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Abstract
Treatment of chickens, ducklings and turkey poults
with furazolidone (0.04% w/w, in the feed) for 10 days
inhibited monoamine oxidase (MAO) activities in the
alimentary tract, heart and brain. Only in the duckling
was an inhibition of MAO activity found in the liver.
In the chicken and duckling, furazolidone (200 mg/kg)
by crop tube inhibited MAO activities in the duodenal
mucosa, liver, heart and brain, whereas the same dose of
the drug given intramuscularly to the chicken was
ineffective. Furazolidone by crop tube was about
equipotent as an MAO inhibitor in chickens, ducklings and
turkey poults. Pretreatment of chickens and ducklings
with neomycin to suppress the alimentary microflora
reduced the effect of furazolidone on MAO activity,
suggesting that the microflora transformed the drug to
an active metabolite which subsequently inhibited MAO
activities in other organs.
Furazolidone (0.04% w/w, 10 days) increased the
amount of 5-hydroxytryptamine (5-HT) in the brain of
chickens and ducklings, and potentiated the vasopressor
action of tyramine in chickens. The amounts of nor¬
adrenaline and adrenaline in the brain were unaffected
by the treatment, as were the actions of noradrenaline,
5-HT, histamine and tryptamine on blood pressure.
In poultry, furazolidone (0.04% w/W, 10 days)
produced an anorexia and an increase in the concentrat¬
ions of pyruvate and lactate in blood. The activation
of transketolase by thiamin pyrophosphate was greater in
haemolysates from furazolidone-treated chickens than in
control preparations. These observations suggested a
deficiency of thiamin in the furazolidone-treated birds.
However, intramuscular administration of thiamin HC1
(84 yg/kg, twice daily for 10 days) to the chicken did
not prevent the development of signs characteristic of
its deficiency.
In chickens given furazolidone (0.04% w/w, 10 days),
the weights of the adrenal and thyroid glands (as % of
body weight) and the oxygen consumption of hologenized
heart were all increased.
Furazolidone (0.04% w/w, 10 days) did not produce
an anaemia or affect the arterial blood pressure in the
conscious chickens, and the activities of plasma
aspartate transaminase and hepatic aminopyrine
demethylase were unaffected. Ducklings survived when
furazolidone was given in the feed at a concentration
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1. The addition of furazolidone to the feed at a con¬
centration of 0.04% w/w for 10 days inhibited monoamine
oxidase (MAO) activities in the alimentary tract, heart
and brain of chickens, ducklings and turkey poults.
In the chicken, the MAO inhibition was most marked in
the rectal caeca and least in the liver, where no inhib¬
ition was found. Only in the duckling was an inhibition
of the enzyme activity found in the liver.
2. Furazolidone (200 mg/kg) administered to chickens
and ducklings by crop tube inhibited MAO activities in
duodenal mucosa, liver, heart and brain. The same dose
of furazolidone injected intramuscularly did not inhibit
MAO activity in the chicken. Furazolidone (by crop
tube) was about equipotent as an inhibitor of MAO
activity in the chicken, duckling and turkey poult.
3. Pretreatment of chickens and ducklings with
neomycin by crop tube to suppress the alimentary flora
reduced the effect of furazolidone on MAO activity,
suggesting that the drug was transformed by the alimentary
flora to an active metabolite which subsequently inhibited
MAO activity in other organs. However, pretreatment of
chickens with intramuscular neomycin did not antagonize the
inhibition of MAO activity produced by furazolidone
(200 mg/kg, crop tube).
4. Furazolidone (0.04% w/w, 10 days), probably in
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consequence of the MAO inhibition, increased the amount
of 5-hydroxytryptamine (5-HT) in the brain of chickens
and ducklings and potentiated the vasopressor action
of tyramine in the chicken. The amounts of adrenaline
and noradrenaline in the brain were unaffected by the
treatment, as were the actions of noradrenaline,
histamine, 5-HT and tryptamine on the blood pressure.
5. Furazolidone CO.04% w/w, 10 days) reduced the feed
intake and growth of chickens, ducklings and turkey
poults. The growth of chickens fed ad libitum with
furazolidone (0.04% w/w) was similar to that of birds
pair-fed with unmedicated diet, indicating that anorexia
was mainly responsible for the reduction in growth in
the drug-treated birds. Methergoline (an antagonist
of central actions of 5-HT) did not affect the anorexia
in the furazolidone-treated chickens, suggesting that
it might not be an outcome of the increase in brain 5-HT.
6. Treatment of chickens with furazolidone (0.04% w/w,
10 days) increased the concentrations of pyruvate and
lactate in blood, and the activation of transketolase by
thiamin pyrophosphate in haemolysates. These signs
together with the anorexia suggested a borderline
deficiency of thiamin. However, the administration of
thaimin HC1 at a dose above the requirement of the birds
(84 pg/kg, i.m. twice daily for 10 days) did not reverse
the signs of its possible deficiency. It seems that
furazolidone might have interfered with the utilization
of the vitamin.
7. In the chicken, the weights of the adrenal and
thyroid glands (as % of body weight) were selectively
increased following administration of furazolidone
CO.04% w/w, 10 days). The increase in the weight of
the adrenal glands most probably represents hypertrophy
of the cortex, as the amount of catecholamines in the
glands was unaffected by furazolidone.
8. The oxygen consumption of homogenized heart was
increased when the chickens were pretreated with
furazolidone (0.04% w/w, 10 days), whereas the utilization
of oxygen by other tissues was unaffected by the treatment.
9. Furazolidone CO.04% w/w, 10 days) did not produce
anaemia or affect the arterial blood pressure in
conscious chickens.
10. The activities of hepatic aminopyrine demethylase
and plasma aspartate transaminase were unaffected by
furazolidone (0.04% w/w, 10 days) in the chicken.
11. Although furazolidone is considered highly toxic
in the duck, in the present experiments ducklings
survived when it was given in the feed at a concentration
of 0.04% w/w for 10 days or by crop tube at a dose of
200 mg/kg. It is suggested that the husbandry of the
duck affects its susceptibility to furazolidone.
1.
Introduction
In a world with an increasing population and
consequently ever-increasing demand for animal protein,
poultry production occupies an important place. The use
of drugs as additives to poultry feed has significantly
contributed to the rapid developments in the quality and
quantity of poultry products, by virtue of increasing feed
conversion and reducing mortality of growing birds. The
addition of furazolidone to poultry feed is recommended
for the therapy and prevention of certain protozoal and
bacterial diseases.
Furazolidone; history and properties
Furazolidone [3-(5-nitrofurfurylidene amino)-2-
oxazolidone] (fig.l) is a member of a group of drugs known
as the nitrofurans which are synthetic organic compounds
obtained initially from furfural, an agricultural
by-product from corn and oat husks. The activity of
these compounds as antimicrobial agents was first studied
by Dodd & Stillman (1944), who noted that a nitro-group in
the 5-position of 2-substituted furans conferred
antibacterial activity on the compounds. The addition of
various side chains to the 2-position of the furan ring
largely governs the chemical properties (solubility,
melting point, etc.) and clinical usefulness of the
nitrofurans. Although more than 3500 nitrofurans have
been synthesized, only a few have found a place in
chemotherapy. The antimicrobial properties of
2.
furazolidone was first reported by Yurchenco, Yurchenco &
Pieopli (1953) . Thereafter, several reports on the
antimicrobial properties of this drug in different
animal species appeared in the literature.
The physical properties of furazolidone include a
molecular weight of 225.2 and a melting point of 255°C.The
drug is an odourless yellow crystalline powder. It is
initially tasteless but a bitter aftertaste follows.
Furazolidone is only sparingly soluble in water, ethanol
and organic solvents (the aqueous solubility at pH 5.0
is 40 mg/ml at 25°C). In dilute solution, the drug is
unstable to light (Paul & Paul, 1964) .
There is little information on the pharmacology of
furazolidone in poultry although the drug is commonly
used in the prevention and treatment of many diseases.
The following review attempts to survey the work which
has been reported on this drug in man and animals, with
special emphasis on avian studies.
Methods for the estimation of furazolidone and their
validity
Buzard, Vrablic & Paul (1956) have reported a method
for the determination of furazolidone in plasma which
depends on the formation and colorimetric estimation of
5-nitro-2-furaldehyde phenylhydrazone (NFP). Using
this method, 'furazolidone' was detected in rat plasma at
levels of 3.3, 3.6, 1.3 and 1.6 yg/m£ at 4, 8, 16 and 24
h, respectively, following a single oral dose of 500 mg/Kg.
This method had to be modified because it was found
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difficult to apply in highly pigmented tissues like liver
due to non-specific colorimetric interference. Chromato¬
graphic columns were used to separate the phenylhydrazone
from non-specific liver chromogen (Herrett& Buzard, 1960).
This method allowed the detection of the 'drug' in
concentrations as low as 0.5 yg/g tissue and permitted the
quantitative determination of 'furazolidone' at 1-5 Ug/g
tissue, and this has been used for the determination of
'furazolidone' in chicken tissues.
A method of analysis (Beckman, 1958) that makes use of
the colours produced when furazolidone is treated with
strong alkalis has been described, but is difficult to
apply due to the instability and lack of reproducibility
of the colours.
A bioassay of furazolidone made use of the inhibition
of growth of drug-susceptible organisms, such as Escherichia
coli or Staphylococcus aure us (Paul & Paul, 1964) .
Hollifield & Conklin (1968) reported a method for the
determination of furazolidone which depends on the fact
that when the drug is mixed with p-diisobuty1-
cresoxyethyoxyethy1 dimethylbenzy1 ammonium hydroxide
(Hyamine hydroxide), it exhibits an absorption maximum at
600 nm. Using this method, they could not detect
furazolidone in dog or human urine following oral adminis¬
tration of 5 mg furazolidone/Kg. Recoveries of the drug
(2-50yg/m£) added to dog or human urine were 99 and 102%,
respectively. For comparison, the urine samples were
also analyzed for furazolidone by methods in which the drug
is converted to its phenylhydrazone (NFP) (Nakamura &
Inoue, 1961; Buzard et al, 1956). The presence of
materials convertible to NFP was confirmed in human and
dog urine following furazolidone treatment. Hollifield &
Conklin (1968) concluded that the (NFP) methods for
detecting furazolidone are not specific, and often measure
metabolite (s) of the drug rather than the drug itself.
Absorption, metabolism and excretion of furazolidone and
its metabolites
Furazolidone is only very sparingly soluble in water,
alcohol, or organic solvents. It is not surprising, then
that it is poorly absorbed from the gastrointestinal tract
mucosal membranes, or through intact skin (Omer, 1978).
The absorption of a nitrofuran drug depends in part on the
solubility of the compound in the contents of the
alimentary tract, and on the rate of its degradation in
the mucosae of the small intestine (Tatsumi, Ou, Yamaguchi
& Yoshimura, 1973).
Studies with rat tissues in vitro (Rogers, Belloff,
Paul, Yurchenco & Gever, 1956) have shown that All tissues
with the exception of blood, rapidly degrade furazolidone.
When furazolidone was given to colostomized chickens at
an oral dose of 30 mg/Kg, it was rapidly and extensively
metabolized and the metabolites excreted in urine (Craine
& Ray, 1972). In these experiments faecal excretion of
furazolidone metabolites was not examined.
Following an oral administration of furazolidone
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(5 mg/Kg) to man and dog, the drug could not be detected
in urine (Hollifield & Conklin, 1968). However,
chromatography of these urine samples revealed the presence
of 2 metabolites. One matabolite was yellow and the other
was orange in appearance under U. V. light. The two
metabolites were present in different relative amounts in
man and dog urine and they demonstrated little inhibitory
activity against Escherichia coli, against which furazolidone
exhibits significant inhibitory activity. Tennent & Ray
(.1971) found that in swine, orally administered furazolidone
is excreted in the form of a large number of metabolic end
14
products. When furazolidone labelled with C was given
orally to a pig, 71% and 19% of the labelled dose was
recovered (as metabolites) in urine and faeces, respectively.
Drug residues in furazolidone-treated birds
Data on drug residues in furazolidone-treated birds
1k*
were obtained usingj_ (NFP) method}which is of dubious
validity as it does not distinguish between the parent
drug and its metabolites. Thus it seems that the 'drug'
levels reported represent furazolidone plus certain
metabolites.
No evidence of accumulation of 'furazolidone' was
obtained in eggs or tissues of hens receiving furazolidone
at a dose of 0.05% w/w for 28 days (Belloff, Buzard &
Roberts, 1953). However, other workers (Kreig & Loliger,
1973) using a similar analytical method, reported that
residues of 'furazolidone' (2.0-2.5 yg/mI of blood and
0.06-0.16 yg/g tissue) were present in chickens given the
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drug at single oral doses ranging from 20-200 mg/Kg, or in
the feed at concentrations of 0.04% w/w for 7-14 days.
In all cases blood and tissues were free from residues
2 days after withdrawal of the drug. It was also
reported (Krieg, 1972) that hens receiving furazolidone at
an oral dose of 20-100 mg/bird for 8 days laid eggs
containing 15-70 yg of the 'drug' and that levels in the
eggs declined to nil 5-6 days after withdrawal of the drug.
Antimicrobial properties of furazolidone
Furazolidone is endowed with antimicrobial activity
against a wide variety of microorganisms. In vitro, the
drug was shown to be active against the gram-ve organisms,
Escherichia coli, Klebsiella, Salmonella, Shigella,
Enterobacter, Bacteriodes and Camp\jJLo.bacter cholera.
A lower order of activity was found with Proteus. It is
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also active against/gram+ve bacteria Staphylococcus and
Streptococcus and against the protozoa Trichomonad and
Giardia (Chamberlain, 1976). In man, the drug has found
many applications in the tropics as an antimicrobial agent
in the alimentary tract and vagina (Ponce de Leon, 1957;
Schneierson & Bryer, 1959; Limaye, 1980). The drug is
also given orally against a wide range of gastrointestinal
diseases of poultry, pigs, horses and foxes (Omer, 1978).
A brief summary of the therapeutic and prophylactic uses
of furazolidone in poultry is given in table (1).
Toxicity of furazolidone
The following is an account of some of the toxic
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effects produced by furazolidone, which have been reported
in some mammalian and avian species.
Toxicity in mammals In rats, furazolidone at an oral
dose of 50 mg/Kg inhibited 81% of the activity of
monoamine oxidase (MAO) in the liver (Stern, Hollifield,
Wilk & Buzard, 1967) , and at a higher dose (500 mg/Kg)
produced 95% inhibition of MAO activity in both liver and
brain of rats (Palm, Magnus, Grobecker & Jonsson, 1967).
In man, oral administration of furazolidone (10 mg/Kg for
10 days) caused anorexia, restlessness, disorder of sleep
and orthostatic collapse (Palm & Magnus, 1968) , and higher
doses (80-140 mg/Kg for 15 days) inhibited 85% of MAO
activity in jejunal mucosa, augmented the pressor actions
of tyramine and amphetamine and increased the urinary
excretion of tryptamine (Pettinger, Soyangco & Oates, 1968).
The calf was shown to be highly susceptible to
furazolidone toxicity. The nature of furazolidone toxicity
in this species is different from that in rat and man.
Doses of 4-9 mg/Kg for 40 days (Hoffmann & Frezer, 1974)
or 8.5 mg/Kg for 7 weeks (Hoyashi, Yamane & Sakai, 1976)
caused haemorrhagic diathesis, ascites, changes in
haemogram and lesions in bone marrow, kidney, liver and
lung. Relatively high doses of the drug (20-30 mg/Kg)
caused tonic spasms and excitation (Hoffmann, Reinacher &
Dirkenson, 1977). In calves and pigs, furazolidone at
doses of 5 or 10 mg/Kg influenced the extrasecretory
function of the pancreas (Kbomenko, 1979). It
decreased the volume of the pancreatic fluid of both species
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and increased the proteolytic activity of that of pigs.
A nervous syndrome was observed in a herd of sows
which had been given furazolidone in the feed at a
concentration of 0.63% w/w 7-10 days post-weaning
(Borland, 1979). The toxic signs observed were ataxia,
crouching, 'goose-stepping', leaping high in the air,
and lying on the ground on their sides. Affected
animals recovered within a few days on withdrawal of
the drug.
It seems that the dog and G. pig are not very
susceptible to furazolidone toxicity. In G. pigs, high
doses ranging from 735 - 2,025 mg/Kg for 7 days reduced
the body weight by 16% and caused some histopathological
changes in testes, adrenals and stomach (Koeda, Saskai,
Kohanwa & Konnon, 1976). A dose of 7.5 mg/Kg for 6 months
did not produce any clinical signs in the dog, although
some histopathological changes in the central nervous
system and testes were noted, and a single oral dose of
200 mg/Kg resulted in emesis in half the animals tested
(Rogers et al, 1956).
Furazolidone has been reported to be carcinogenic to
rats and mice when it is given continuously over a year or
for life (Anonymous, 1976 a, b). Initial studies showed
that, following furazolidone treatment (0.15% w/w for one
year) breast tumors were induced in female rats. Lifetime
studies were also conducted in two strains of rat and
these showed that furazolidone given in the feed (at
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several doses up to 0.1% w/w) caused a significant
increase in the incidence of breast tumors (particularly
adenocarcinomas) in the female, and that the incidence
was dose-related. In mice, however, furazolidone (up
to 0.03% w/w in the feed for life) induced bronchial
adenocarcinoma in both sexes.
Toxicity in birds
The recommended therapeutic dose of furazolidone in
chickens and turkeys is 0.04% w/w in the feed for 10 days,
and in ducks, 0.01% w/w in the feed for 7 days (Veterinary
Data Sheet, 1980). The drug at doses equivalent to or
slightly above the therapeutic level has been reported to
cause toxic signs in birds. These are summarized
below:-
1. Toxicity in chickens
Radchuck (1965) reported signs of toxicity in chicks
and hens 4-6 h after oral administration of 300 mg/Kg.
The birds became inappetent, drowsy and unaware of the
surrounding environment. These signs were followed by
paralysis and death. The of the drug was found to
be 380 mg/Kg, and 500 mg/Kg was lethal to all the birds
studied. However, Harwood & Stunz (1954) estimated that
the of furazolidone in the chicken was 500 mg/Kg.
The effect of furazolidone on chicken growth was first
studied in 1953, when it was shown that feeding furazolidone
at a low level (0.006% w/w for 10 weeks) did not cause a
beneficial effect on growth of chickens kept in^clean
environment (Jacobs, Elam, Andreson, Gee, Fowler & Couch,
1953). Subsequently, this observation was confirmed by
other workers (Harwood & Stunz, 1954; Cooper & Skulski,
1956). It has also been shown (Harwood & Stunz, 1954;
McDonald & Beilharz, 1961; Ehlhardt, Beuving & Haye, 1975;
Jensen, Chang & Washburn, 1975) that feeding furazolidone
at levels of 0.033% w/w for 4 weeks or 0.04% w/w for
variable periods caused a significant reduction in growth.
The cause of this has been attributed to impaired digestion,
absorption or metabolism in the birds. Sauer, Jensen &
Schutze (1969) reported a significant reduction in the
weight of eggs from chickens fed furazolidone at a
concentration of 0.003 - 0.011% w/w for 4-6 weeks. More
recently, Czarnecki & Sujarit (1979) showed that
furazolidone (60 pg or more) injected into the chicken egg
at 40 and 72 h of incubation, significantly reduced the
growth and increased the glycogen level in the chicken
embryo.
Furazolidone treatment (0.055% w/w in the feed for
4 weeks) caused ascites and a 30% mortality (Harwood,
Stunz & Wolfgang, 1958), and at a concentration of 0.04%
x
w/w for 6 weeks, the drug causedJ_cardiomyopathy associated
with cardiac dilation and ascites (Feron & Van Stratum,
1966). A small increase (4.4%) in the heart weight was
reported by Francis & Schaffner (1956) following
furazolidone feeding (0.017% w/w for 3 weeks). Other
workers (Jensen et al, 1975) , however, were unable to
confirm these effects on the heart when furazolidone was
fed to chickens at a concentration of 0.07% w/w for
4 weeks.
Nervous signs (unspecified) were observed in chicks
fed furazolidone at a concentration of 0.2% w/w for 1-13
days (Smith, 1955, cited by Cooper & Skulski, 1956.)
A small but significant reduction in packed cell
volume and haemoglobin content was reported by Ehlhardt
et al (1975) when furazolidone was fed to chickens at a
level of 0.04% w/w for 3 weeks. No anaemia was found,
however, in chicks fed furazolidone (0.01-0.07% w/w for
4 weeks by Jensen, et al (1975).
Reports on the effect of furazolidone on the weight
of the thyroid gland are at variance. Mellen & Waller
(1954) noted a 24% increase in the weight of the gland
when furazolidone was fed at a level of 0.011% w/w for
8 weeks. However, Francis & Schaffner (1956), reported
a 14% reduction in the thyroid weight following
furazolidone treatment (0.022% w/w for 4 weeks).
Cooper & Skulski (1955, 1956) fed furazolidone at
concentrations of 0.005-0.08% w/w for variable periods up
to 27 weeks, and noted a reversible retardation of
spermatogenesis and a significant reduction in the testes
weights. The drug did not seem to have an adverse
effect on the fertility of the birds or the hatchability
of the eggs.
2. Toxicity in turkeys
Cardiomyopathy and cardiac dilation seem to be the
major toxic signs of furazolidone in turkeys. Several
workers (Jankus, Noren & Staley, 1972; Czarnecki, Jankus
& Hultgren, 1974; Czarnecki, Reneau & Jankus, 1975;
Jensen et al, 1975) have found that cardiomyopathy
(right and left ventricular dilation), ascites, growth
depression, and death occurred when turkey poults were
fed furazolidone at concentrations ranging from G.03-0.07%
w/w for 3 weeks or more.
Furazolidone has been shown to produce some biochemical
changes in turkeys. Staley, Noren, Bandt & Sharp (1978)
reported that feeding furazolidone (0.05% w/w for 4 weeks)
caused a disordered hepatic metabolism, as judged by a
lowering of total plasma proteins, an increased activity
of aspartate transaminase in serum and an increase in the
level of glycogen in the liver. These effects have been
confirmed by Simpson, Rollinghoff, Preisig & Fisher (1979),
who also showed that furazolidone treatment (0.05% w/w for
24 days, followed by 0.07% w/w for 42 days) resulted in
hypotension and a decrease in the proteins and trypsin
inhibitory factor in the plasma.
3. Toxicity in ducks
Acute toxicity has been reported in mallard ducklings,
aged 4-6 weeks, following administration of furazolidone
(100 mg/bird) on 2 successive days (Lucas, 1956).
On the first day of treatment, no adverse effects were
noted. However, within 15-30 minutes of the second
dose, the birds would jump up, run blindly into fences
or other objects, whirl around in circles, fall down,
and after lying motionless for a time, would eventually
arise and act normal. Dougherty (1956) reported
toxic signs (unspecified) in ducklings fed furazolidone
at a concentration of 0.022% w/w for 10 days. It has
also been reported that treatment of ducklings with
furazolidone (0.062% w/w - 0.092% w/w for 18 days)
resulted in depression or excitation, mobility
disturbance and death (Kriz, Branda & Svestka, 1968).
4. Toxicity in pigeons
Pigeons seem to tolerate high doses of furazolidone
(Timchenko, 1968). Toxic signs appeared 3 hours after
an oral dose of 1 g/Kg and continued for 24 hours.
These signs were nervous in nature and included depression,
incoordination of movement and drowsiness. One bird out
of 6 died when 1.5 g/Kg was given orally. In the rest
there were nervous signs, anorexia and diarrhoea. The
LDj-0 of furazolidone in pigeons was found to be 2375 mg/Kg.
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Aims of the present study
Despite the widespread use of furazolidone in poultry,
its pharmacology seems to have received insufficient attention
in these species. This warranted a pharmacological study of
furazolidone in poultry, re-examining some of the effects
described before and searching for further pharmacological
and biochemical actions of the drug.
Materials
Animals
Chickens (T-line) and turkey poults (Ross Super-
Midi Breeder hybrid) were obtained from the Poultry
Research Centre, Roslin. Duck eggs (Alesbury, Khaki-
Campell and Indian Runner) were bought from farms in
Dalkeith and Saline and hatched in an incubator in the
Department of Veterinary Pathology.
The birds were housed in the Wellcome Animal
Research Unit in cages containing a deep litter of
white wood shavings. Each cage (110 x 70 x 60 cm)
accommodated 3-4 birds. In some experiments, cages
were divided with a wire mesh and one bird accommodated
in each half. The individually-housed birds had visual
and auditory contact with each other. Chickens were
kept at a temperature of 21°-24°C, and chicks, ducklings
and turkey poults at 24°-28°C, with 50-60% relative
humidity and lOh of artificial light daily.
The chickens were fed a layer mash supplied by
McGregor & Co (Leith), Quayside Mills, Leith, Edinburgh;
and chicks, ducklings and turkey poults were given the
appropriate 'starter' ration supplied by the Poultry
I
Research Centre (Roslin). All the diets were free
from growth-promoting and anticoccidial agents, and
were usually available to the birds ad libitum.
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In one experiment chickens (7% weeks old) were
housed singly and fed ad libitum with unmedicated feed
or feed containing furazolidone (0.4% w/w) for 10 days.
The growth and feed intake of the birds were recorded
daily, and the values for the feed intake used subse¬
quently for a "paired-feeding" experiment. In this
experiment the chickens were provided daily with a
measured amount of unmedicated feed, which was equivalent
to that consumed by the control or the furazolidone-
treated birds.
Drugs and Chemicals
The drugs and chemicals used were :- acacia
(M & B, Laboratory Chemical), acetylacetone, redistilled
(Koch Light Laboratory, Laboratory Reagent),
(+) adrenaline hydrogen tartarate (B.D.H., Biochemical
grade), amberlite resin, CG^q/ hydrogen form, mesh size
100-200 (B.D.H., Chromatographic grade), 4-aminophenazone
(B.D.H., Laboratory Reagent), aminopyrine (4-dimethylamino-
antipyrine, 97% w/w) (Ralph N. Emanual), ammonium
acetate (B.D.H., Analytical Reagent), ammonia solution
(about 35% NH^) (B.D.H., Analytical Reagent), anthrone
(Sigma), ascorbic acid (B.D.H., Analytical Reagent),
L-aspartic acid (Sigma), barium hydroxide (B.D.H.,
Analytical Reagent), cholestrol (Sigma),
cyanomethaemoglobin (B.D.H., Clinical Reagent), a-ct'-
dipyridyl (Sigma), dopamine (3-hydroxytyramine) (Sigma),
ferric chloride, hexahydrate (B.D.H., Analytical Reagent),
formaldehyde, 40% w/v solution (B.D.H., Analytical
Reagent), furazolidone (micronized preparation, particle
size 5 ym) (Eaton Laboratories), a premix containing
furazolidone, 4% w/w (Neftin) (Eaton Laboratories),
D-glucose (B.D.H., Analytical Reagent), glucose oxidase
(Sigma), D-glucose-6-phosphate monosodium salt (Sigma),
glycine (B.D.H., Biochemical grade), Halothane
(Fluothane) (I.C.I.), heparin sodium (Sigma), histamine
dihydrobromide (Sigma), hydrazine hydrate (B.D.H.,
Analytical Reagent), 5-hydroxytryptamine creatinine
sulphate (B.D.H., Biochemical grade), 4-hydroxyquinoline
(Sigma), hydrochloric acid (B.D.H., Micro Analytical
Reagent), a-ketoglutaric acid (2-oxoglutaric acid) (Sigma),
kynuramine dihydrobromide (Sigma), lactate dehydrogenase,
III (Sigma), L (+) lactic acid (Sigma), magnesium chloride,
hexahydrate (B.D.H., Analytical Reagent), magnesium sulphate,
heptahydrate (B.D.H., Analytical Reagent), malate
dehydrogenase (Sigma), metaphosphoric acid (B.D.H.,
Laboratory Reagent), methergoline (Farmitalia),
neomycin sulphate, 70% w/w, soluble powder, veterinary
(Squibb & Sons, Ltd), nicotinamide (nicotinic acid amide)
(Sigma), nicotinamide adenine dinucleotide, reduced form
(NADH), grade III (Sigma), nicotinamide adenine
dinucleotide phosphate (NADP), monosodium salt (Sigma),
(-) noradrenaline hydrogen tartarate (Sigma),
orthophosphoric acid, 80% (B.D.H., Analytical Reagent),
Orcinol, crystalline (Sigma), perchloric acid, 71-73% w/w
(B.D.H., Analytical Reagent), peroxidase, salt-free
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powder, type I, from horseradish (Sigma), phenobarbitone
sodium (B.D.H., Laboratory Reagent), phenol (B.D.H.,
Analytical Reagent), potassium carbonate (B.D.H.,
Analytical Reagent), potassium chloride (B.D.H.,
Analytical Reagent), potassium dichromate (B.D.H.,
Analytical Reagent), potassium dihydrogen orthophosphate
(B.D.H., Analytical Reagent), potassium ferricyanide
(M & B, Laboratory Reagent), potassium hydroxide (B.D.H.,
Analytical Reagent), potassium phosphate (B.D.H.,
Laboratory Reagent), ribose (Sigma), ribose-5-phosphate
monobarium salt (Sigma), semicarbazide HCl (B.D.H.,
Analytical Reagent), sodium bicarbonate (B.D.H., Analytical
Reagent), sodium chloride (B.D.H., Analytical Reagent),
di-sodium hydrogen orthophosphate dihydrate (B.D.H.,
Laboratory Reagent), sodium hydroxide (B.D.H., Analytical
Reagent), sodium pyruvate (Sigma), sodium sulphate,
decahydrate (B.D.H., Analytical Reagent), sodium
tung State (B.D.H., Analytical Reagent), Sulphuric acid
(B.D.H., Analytical Reagent), thiamin (Sigma), thiamin
pyrophosphate (Sigma), thiourea (Griffin & George,
Laboratory Reagent), trichloroacetic acid (B.D.H.,
Analytical Reagent), tris (hydroxymethyl) amino-methane
(B.D.H., Analytical Reagent), tryptamine HCl (Sigma),
tyramine HCl (Sigma) and zinc sulphate (B.D.H., Analytical
Reagent).
Buffers and Solutions
0.5M phosphate buffer solution, pH 7.4, was made
by mixing 0.5 M Na2HP04.2 H20 (80.3 ml) and 0.5 M KH2P04
(19.7 ml). 0.057 M phosphate buffer solution, pH 7.4,
was obtained by mixing 1 N HC1 (13.3 ml) and 0.25 M
Na2HP04 (267 ml) and making up to 1 litre with distilled
water. 1 M phosphate buffer, pH 7.4, was made by
dissolving KH2P04 (136 g) and NaOH (33 g) in distilled
water and the volume adjusted to 1 litre. 0.01 M
phosphate buffer, pH 7.0, was prepared by mixing 0.2 M
NaH2P04 (3.9 ml) and 0.2 M Na2HP04 (6.1 ml), and making
up to 200 ml with distilled water. 0.75 M Tris buffer,
rcxp [J
pH 7.4, was made by dissolving Trisfamrnomethane (90.8 g)
in 1 litre of distilled water. 1 M sodium acetate
buffer, pH 6.5, was made by dissolving NaOH (40 g) in
distilled water (900 ml) and glacial acetic acid (60 ml),
and the volume made up to 1 litre with distilled water.
0.1 M phosphate buffer, pH 7.2, was obtained by mixing
0.1 M KH2P04 (29.6 ml) and 0.1 M Na2HP04.2H20 (70.4 ml).
0.5 M Glycine-0.4 M hydrazine buffer was made by
dissolving glycine (37.5 g) and hydrazine hydrate (20 ml)
in distilled water (300 ml), and adjusting to pH 9.0 with
NaOH before making up the solution to 1 litre with
distilled water. The saline-phosphate medium used in
the estimation of transketolase activity was made by
dissolving NaCl (2.81 g), KC1 (9.26 g), K2HP04 (2.73 g)
and MgS04.7H20 (0.30 g) in distilled water and adjusting
the pH to 7.4 with 1 N HC1. The volume was made up to
20.
a litre with distilled water.
The pH of the buffer solutions was measured at a
glass electrode (Albert Measurements Ltd, Model 40), or
by using narrow range indicator papers (Whatman, B.D.H.
Chemicals).
Mixing Furazolidone with the Food
Furazolidone was fed to the birds at a concentration
of 0.04% w/w for 10 days. A premix (Neftin) containing
4% w/w furazolidone was thoroughly mixed with the food
(mash) using a pestle and a mortar. Enough food was
mixed with the drug to last 5 days. Before the medicated
food was given to the birds, it was remixed to ensure an
even distribution of the drug in the food.
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Assay of monoamine oxidase (MAO) activity
The method used for the estimation of MAO activity
was that of Krajl (1965) which is based on monitoring
fluorometrically the appearance of 4-hydroxyquinoline
which arises from the spontaneous cyclization of the



















The intramolecular (non-enzymatic) condensation of
the amino aldehyde to 4-hydroxyquinoline is faster than
the further oxidation of the aldehyde to the acid or
4-hydroxy-2(1 H)_quinoline (Weissbach, Smith, Daly,
Witkop & Udenfriend, 1960).
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Preparation of tissues
The birds were killed by decapitation and the tissues
rapidly removed and chilled on ice. The lumen of the
duodenum was washed through with chilled saline before
cutting it open and scraping away the mucosa with a glass
slide. The heart was opened and blotted with filter
paper to remove blood. The tissues were cut into small
pieces and homogenized with 6 strokes in a teflon / 31 A ii
homogenizer in an ice bath. Homogenates (20% w/v) of
each organ in 0.5 M phosphate buffer (pH 7.4) were
prepared, and the appropriate dilutions made in the same
buffer for the estimation of MAO activity.
Incubation medium
The incubation medium contained, 0.5 M phosphate
buffer, pH 7.4 (0.5 ml), tissue homogenates (1 ml
equivalent to 0.78 mg duodenal mucosa, 3.13 mg liver or
brain or 12.5 mg heart), 0.02% w/v kynuramine dihydrobrom-
ide (0.5 ml) and distilled water to 3 ml.
An incubate without substrate served as the blank.
The reaction mixtures were incubated at 37°C for 30
minutes under air and with shaking. The incubates were
then deproteinized with 0.6 M perchloric acid (2 ml), as
recommended by Century & Rupp (1968), followed by centri-
fugation at 900 g for 10 minutes at 5°C in a low-speed
centrifuge (MSE MISTRAL 2L) . Supernatant (1 ml) was
mixed with IN MaOH (2 ml) and placed in a quartz cuvette.
The solution was activated at 315 nm and the peak in the
fluorescence scan at 380 measured in an Aminco-Bowman
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spectrofHucrimeter. The presence of substances affecting
the fluorescence of 4-hydroxyquinoline was sought by
mixing equal volumes of tissue blank and 4-hydroxyquinoline
solution. In all cases the fluorescence of the mixture
was half that of the undiluted solution of 4-hydroxy¬
quinoline, demonstrating an absence of augmentation or
quenching of fluorescence.
Internal standards of 4-hydroxyquinoline (0.25, 0.50,
1.0 and 2.0 yg/ml) were taken through the procedure
described above, and a graph relating 4-hydroxyquinoline
concentration with fluorescence intensity was constructed
with every batch of tissue homogenates (fig.2 ). From
this curve, fluorescence readings were converted to
amounts (yg) of 4-hydroxyquinoline.
MAO activity (y mol 4-hydroxyquinoline/g tissue/h)
was obtained from the expression:-
4-hydroxyquinoline in medium x 2 x 1000
^Molecular wt. of 4-hydroxyquinoline x wt. of tissue (mg).
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Measurement of aminopyrine demethylase activity in the liver
The activity of aminopyrine demethylase was measured
by a method described by Mazel (1971) , in which the
production of formaldehyde from the demethylation of the
substrate aminopyrine is measured spectrophotometrically.
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The formaldehyde formed was trapped as the
semicarbazone and measured by the colorimetric

























Chickens (8 weeks old) were decapitated and pieces
of liver excised, weighed and homogenized with chilled
isotonic KC1 (1.15% w/v) in a Teflon^ homogenizer. The
homogenates (25% w/v) were centrifuged at 10,000 g for
10 minutes at 5°C to remove nuclei and mitochondria.
The microsome-rich supernatants were used for the
enzyme assay.
Incubation procedure
A solution (1 ml) containing aminopyrine (13.88
mg/ml) and magnesium chloride (5.07 mg/ml) was pipetted
into a 25 ml flask standing on ice, together with 3ml
of a solution containing NADP (0.166 mg/ml), glucose
6-phosphate (0.94 mg/ml), nicotinamide (2.034 mg/ml)
and semicarbazide HC1 (2.23 mg/ml) in 0.5 M phosphate
buffer, pH 7.4; and to these was added 2 ml of 10,000 g
liver supernatant. Tissue blanks were prepared in
which distilled water (1 ml) was substituted for the
solution containing aminopyrine and MgC^. The
reaction mixtures were incubated in a water bath at
37°C for 30 minutes with shaking. The reaction was
stopped by the addition of 15% w/v zinc sulphate (2 ml),
and the contents of the flasks were mixed and left 5
minutes before a saturated solution of barium hydroxide
(2 ml) was added to each flask with mixing. After 5
minutes the contents of the flasks were transferred to
centrifuge tubes and spun down at 900 g for 15 minutes
at 5°C. An aliquot of the supernatant (5 ml) was
transferred to another flask which contained Nash
Reagent (30% w/v ammonium acetate and 0.3% v/v
acetylacetone) (2 ml). The contents of the flasks were
mixed and incubated in the dark in a water bath for 1
hour at 37°C with shaking, to allow the development of
yellow colour.
Standard solutions of formaldehyde (0.5, 1, 2 and
(fig.3)
4 Vg/ml) were prepared in each experiment/ An aliquot
of each concentration of formaldehyde (5 ml) and a
blank (distilled water) (5 ml) were mixed with Nash
Reagent (2 ml) and incubated in the dark at 37°C for
1 hour in a water bath with shaking. The absorbence
of the yellow colour was read in a spectrophotometer at
a wavelength of '415 nm with the blank set at zero. The
activity of aminopyrine demethylase in terms of
formaldehyde produced (ymolHCHO/ml*/h) was obtained from
the expression:-
quantity of HCHO produced by 5 ml of x 2
supernatant reacted with Nash Reagent (yg.)
molecular weight of formaldehyde
* 10,000 g supernatant of liver homogenate (25% w/v).
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Estimation of monoamines in organs of chickens and
ducklings
The catecholamines adrenaline and noradrenaline
were estimated in the brains and adrenals by the
trihydroxyindole (THI) method of von Euler & Floding
(1955) in which adrenaline and noradrenaline are oxidized
in a buffered solution at a slightly acid pH to form
their quinone derivatives, adrenochrome and noradreno-
chrome. In alkaline solution (NaOH), and in the presence
of a reducing agent (ascorbic acid) to prevent oxidation,
these chrome compounds rearrange to form the corresponding
trihydroxyindoles adrenolutine and noradrenolutine.
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The lutines fluoresce strongly under U.V. light, with
characteristic activation and emission spectra. Since
adrenaline will oxidize at a lower pH than noradrenaline,
it is possible to estimate the fluorescence due to
adrenaline in a mixture of the amines.
The estimation of monoamines involved the following
steps:-
1) Extraction of the amines from the tissues.
2) Purification so as to remove all contaminants.
3) Fluorimetric estimation of the catecholamines
and 5-HT present.
Preparation of tissue extracts
Chickens aged 8 weeks or chicks and ducklings aged
12-17 days were decapitated and the whole brain or
adrenals rapidly dissected out and placed on glass plates
cooled on ice. The tissues were homogenized in ice-cold
0.1 M HC1 (2 ml/g) containing ascorbic acid (5 mg/ml) by
six strokes in a Teflon homogenizer, and diluted with
distilled water to a volume of 11 ml (brain) or 50 ml
(adrenals). Monoamines were extracted as described by
Sharman (1971). Throughout the extraction, the samples
were kept at 4°C and were mixed with a Rotamixer following
each addition of reagent. Two aliquots (5 ml) of each
homogenate were pipetted into nylon centrifuge tubes and
to one aliquot amines were added (2 yg noradrenaline/5 ml
adrenal homogenate or 1 yg noradrenaline and 1 yg 5-HT/5 ml
brain homogenate) to estimate their recovery by the
extraction procedure. Proteins were removed by the
addition of perchloric acid (71-73% w/w) (30 yt/ml) and
centrifugation at 15,000 g for 5 minutes at 0°C. The
clear supernatants were decanted into glass centrifuge tubes
and the pH adjusted to 4 with a dilute solution of
potassium carbonate. The extracts were left for 10 minutes
to allow CO2 to escape before centrifugation at 900 g for
5 minutes to remove potassium perchlorate.
Purification of the tissue extracts:-
A cation exchange resin (Amberlite CG50, ammonium form)
was used for the purification of the extracts. The resin
was prepared as described by Bartlet & Gilbert (1971).
The resin (hydrogen form) was stirred 3 times with 1 M
HCl (3 vols) for 30 minutes and rinsed with distilled water
until the washing was free from chloride. To convert to
the ammonium form, the resin was stirred 3 times with
3 M NH^OH (3 vols) for 30 minutes. The ammonium form of
the resin was washed first with distilled water until the
pH of the effluent fell to about 9 and then with 0.2 M
ammonium acetate adjusted to pH 7.5 with 2 M NH^OH, and
was stored at 5°C under the ammonium acetate buffer.
The supernatants were loaded on the Amberlite columns
(3 x 1 cm), which were placed in the dark and the solutions
allowed to flow through by gravity at a rate not exceeding
0.25 ml/min. They were washed with 0.02 M ammonium
acetate (15 ml) adjusted to pH 7.5 with 0.5 M ammonium
hydroxide, and then with 0.05M sulphuric acid (3 ml) before
eluting the amines with 0.5M sulphuric acid (5 ml). The
brain eluates were divided into two portions for the
estimation of 5-HT and catecholamines, respectively. The
pH of the eluates used for the estimation of catecholamines
were adjusted to 4 with solid sodium bicarbonate, and
stored overnight at -20°C.
Aliquots (5 ml) of solutions of 5-HT (0.05, 0.10 and
0.50 ug/ml) and noradrenaline (0.02, 0.1 and 0.25 yg/ml)
in 0.04 M HCl containing ascorbic acid (2 mg/ml) were
carried through the whole extraction procedure with each
batch of brain homogenates. These served as internal
standards in the estimation of the amines. Internal
standards of noradrenaline (0.5, 2,0 and 4.0 yg/ml)
were prepared with each analysis of adrenal homogenates.
Estimation of monoamines:-
An Aminco-Bowman spectrofluorimeter was used to
measure the fluorophors, and the wavelengths quoted are
uncorrected values. The estimations were carried out
in test tubes washed with detergent and chromic acid
and thoroughly rinsed with distilled water. The
contents of the tubes were mixed with a Rotamixer after
each addition of reagent.
5-HT:-
Concentrated HCl (1 ml) containing ascorbic acid
(0.5 mg/ml) was added to the eluate (2 ml) to make it
3M with respect to HCl, and 5-HT estimated by measuring
the peak in the activation scan at 290 nm, with fluorescence
recorded at 535. With each batch of analyses an
"extraction blank" was prepared by substituting water
for brain homogenates in the extraction, and the blank
values subtracted from the readings before calculating the
amounts of 5-HT.
Adrenaline and noradrenaline:-
Adrenaline and noradrenaline were estimated different¬
ially by the THI method (von Euler and Floding, 1955),
utilizing differences in the oxidation rates of the amines
at a low pH.
One aliquot of eluate (.1 ml) was mixed with 1M
sodium acetate buffer adjusted to pH 6.5 (0.5 ml), and
diluted to 3.0 ml with distilled water. The tube was
placed in the dark for the oxidation of adrenaline and
noradrenaline with potassium ferricyanide (0.25% w/v)
(0.1 ml). After 3 minutes, ascorbic acid (0.2% w/v)
(0.1 ml) and sodium hydroxide (20% w/v) (0.9 ml) containing
1,2-diaminoethane (2% w/v) were added, and the mixture kept
in the dark 7 minutes for fluorophor formation. After
dilution to 5.0 ml with distilled water, the fluorophors
formed from adrenaline and noradrenaline were estimated by
measuring the peak in the fluorescence scan between 510
and 520 nm, with activation at 410 nm.
A second aliquot of eluate (1 ml) was mixed with 1M
sodium acetate buffer adjusted to pH 3.5 (0.5 ml), zinc
sulphate (0.5% w/v) (0.1 ml) and distilled water to 3.0 ml.
At pH 3.5 only adrenaline was rapidly oxidized with
potassium ferricyanide, and treatment with ascorbic acid
and sodium hydroxide containing 1,2-diaminoethane produced
a fluorophor from adrenaline and only 4.9 ± 0.4% of the
noradrenaline (mean ± s.e.m. n = 6).
With each batch of analyses an "extraction blank"
was prepared by substituting water for brain homogenates
in the extraction. The blank values were subtracted
from the readings before calculating the amounts of






flourescence due to noradrenaline
and adrenaline in the eluate, respectively.
A and B = fluroescence readings of the eluates at
pH 6.5 and 3.5, respectively,
n = % noradrenaline oxidized at pH 3.5.
m = ratio of fluorescence intensities of adrenaline/
noradrenaline at pH 6.5.
[The values for n and m were 4.9 ± 0.4 (6) (mean ± s.e.
mean, number of observations) and 1.7 ± 0.0 (6),
respectively.]
A graph relating fluorescence to noradrenaline (yg)
was constructed from the internal standards. The
noradrenaline equivalents of X and Y were read from
this graph, and the value so obtained from Y divided
by m to obtain the equivalent in terms of adrenaline.
X =
Y =
where X and Y =
Validation of the method for the estimation of adrenaline
and noradrenaline in a mixture
The following experiments were carried out to test
the validity of the differential estimation of adrenaline
and noradrenaline when present in a mixture.
1) Determination of the rates of oxidation of adrenaline
and noradrenaline in the presence of ZnSO^ at pH 3.5.
2) The effect of pH on the rate of oxidation of
adrenaline and noradrenaline.
3) Relative fluorescence intensities of adrenaline and
noradrenaline at pH 6.5.
4) Relative fluorescence intensity of dopamine in the THI
reaction.
5) Recovery of amines from the CG50 columns and from the
total extraction procedure.
1) Determination of the rates of oxidation of adrenaline
and noradrenaline in the presence of ZnSO^ at pH 3.5
It has been reported that ZnSO^ increases the rate
of oxidation of adrenaline at pH 3.5, the effect being
dependent on the amount of the catalyst used (von Euler and
Floding, 1955). Preliminary experiments were conducted to
find out the optimum concentration of ZnSO^ which would
give the maximum rate of oxidation of adrenaline (1 yg/ml)
at pH 3.5. ZnSO^ was added to the oxidation mixtures at
concentrations ranging from 0.007 - 0.833 mg/ml and the
relative fluorescence intensities of adrenaline (1 yg/ml)
measured after 3 minutes oxidation with potassium
ferricyanide. The results of this experiment (fig. 4)
showed that about maximal fluorescence intensity was
obtained using ZnSO^ at a final concentration of 0.17 mg/ml,
which was not significantly different from the fluorescence
intensity obtained with 0.83 mg/ml (p > 0.1).
To determine whether full oxidation of adrenaline'
occurred in 3 minutes at pH 3.5 in the presence of ZnSO^
(final concentration 0.17 mg/ml), experiments were carried
out in which oxidation was stopped with ascorbic acid
3', 4', 5', 6', 7', 8', 9' and 10' after adding potassium
ferricyanide. The results of this experiment (fig. 5)
showed that adrenaline (1 yg/ml) was completely oxidized
in 3 minutes giving maximal fluorescence. Noradrenaline
(1 yg/ml), under the same conditions gave a relatively low
fluorescence intensity which increased slowly with time.
2) The effect of pH on the oxidation rate of adrenaline and
noradrenaline
To determine the amount of adrenaline and noradrenaline
present in a mixture, it was necessary to obtain a reliable
value for the percentage of noradrenaline which is oxidized
in 3 minutes at pH 3.5 in the presence of ZnSO^. The two
amines were reacted by the THI method at pH 6.5 and at
pH 3.5 in the presence of the catalyst with 3 minutes of
oxidation, and the fluorescence intensity recorded. It
was found that the percentage of noradrenaline oxidized
at pH 3.5 (with 3 minutes oxidation) was 4.9 ± 0.4 (6).
No significant difference was found between the fluorescence
intensities of adrenaline at pH 3.5 and pH 6.5 (p > 0.1),
indicating that this amine was fully oxidized under both
sets of conditions.
3) The relative fluorescence intensity of adrenaline and
noradrenaline at pH 6.5
For the estimation of adrenaline and noradrenaline
present in a mixture, the relative fluorescence of equal
amounts of the two amines (m) at pH 6.5 must be known.
To obtain a reliable value for Cm), a number of experiments
were performed using concentrations of the two amines
varying from 0.05 yg base/ml to a 5 yg base/ml. The
regression of fluorescence upon amine concentration was
calculated by the method of least square and (m) was found
to have a value of 1.7 (fig. 6).
4) Relative fluorescence intensity produced by dopamine
in the THI reaction
Dopamine is present in the avian brain (Holzbauer &
Sharman, 1971), and in small amounts in the adrenal gland
of some species like ox and sheep (Shepherd & West, 1953).
To find out whether dopamine would interfere with the
estimation of adrenaline and noradrenaline, an experiment
was performed in which relatively high concentration of
dopamine (25, 50 and 100 yg/ml) were reacted by the THI
method at pH 6.5 and pH 3.5, with oxidation time of 3
minutes. For comparison, three concentrations of noradren-
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aline and adrenaline (0.25, 0.5 and 1.0 yg/ml) were
simultaneously reacted at pH 6.5 and 3.5, respectively.
Some of the results of this experiment (fig. 7) show
that dopamine (100 yg/ml) produced little or no fluor¬
escence in the THI reaction, thus, in physiological
amounts it is unlikely to interfere with the estimation
of catecholamines.
5) Recovery of monoamines from the CG50 columns and
from total extraction procedure
The recovery of noradrenaline (1 yg/ml) and 5-HT
(1 yg/ml) from the CG50 columns and after carrying them
through the extraction procedure was investigated.
Aliquots (5 ml) of 5-HT or noradrenaline (dissolved
in distilled water) were put directly dnto the resin
columns, which were washed with 0.02 M ammonium acetate
buffer (15 ml) and 0.05 M H2S04 (3 ml) before eluting
the amines with 0.5 M H^SO^ (5 ml).
Other aliquots (5 ml) of 5-HT or noradrenaline in
0.04 M HCl containing ascorbic acid (2 mg/ml) were mixed
with perchloric acid, 72% w/v CO.15 ml) and the pH
adjusted to 4 with K^CO^. After allowing the solutions
to stand for 10 minutes to enable CO2 to escape, they were
centrifuged at 900 g for 5 minutes at 5°C. The super-
natants were decanted into the resin columns and eluted
as described above.
The results of this experiment (table 2) showed that,
after direct addition to the columns, 5-HT and noradrenaline
were eluted with a percentage recovery of 93.1 ± 2.1
(mean ± s.e.m. n = 5) and 81.8 ± 1.4%, respectively.
These percentage recoveries were significantly less than
100% (p < 0.01 for 5-HT and < 0.001 for noradrenaline).
When the amine solutions were carried through the
extraction procedure, the recoveries of 5-HT and norad¬
renaline were 89.8 ± 0.7% and 78.4 ± 1.8%, respectively.
These recoveries were not statistically different from
those obtained after direct addition of 5-HT and
noradrenaline to the columns (p > 0.1 for both amines).
In 24 experiments, the recovery of 5-HT (1 yg) and
noradrenaline (1 yg) added to brain homogenates was
81.2 ± 2% (mean ± s.e.m.) and 104.0+ 5,0% respectively. It
was noted that the recovery of noradrenaline from the
tissue homogenates was significantly greater than from
the columns (p < 0.001) or total extraction procedure
(p < 0.001), which suggests the presence of a substance (s)
in tissue protecting noradrenaline against losses.
6) Characteristics of the spectra of tissue extracts
The emission spectra obtained from the adrenal
extracts at pH 6.5 and 3.5 had peaks at 510 and 520 nm,
respectively, whichwere the emission peaks of the authentic
noradrenaline (> 1 yg/ml) and adrenaline. In a number of
experiments attempts were made to estimate the catechol¬
amines in the hearts and brains of chickens. The peaks
of the emission spectra in these tissue extracts C490 nm)
was similar to that of internal standards of noradrenaline
at relatively low concentrations (0.05 and 0.1 yg/ml)
(fig. 8A) . This observation was also noted with the
heart and brain extracts in rat and G. pig. It seems
that the wavelength of the peak in the emission spectra
of noradrenaline shifted from 485 to 492 nm as the
amount of the catecholamine increased from 0.05 to 0.2
yg/ml (fig.8B ).
In some preliminary experiments the Dowex-50 resin
was used for the purification'of catecholamines. The
amines were recovered from this resin to the same extent
as the amberlite CG50. As the latter may be used for
the purification of both catecholamines and 5-HT, its
use in all subsequent experiments was preferred.
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Measurement of the vasopressor and vasodepressor actions
of amines in anaesthetized chickens
Pullets aged 17-19 weeks were anaesthetized with
phenobarbitone sodium (180 mg/Kg) which was injected into
a wing vein as a 10% w/v solution in 0.9% w/v aqueous
NaCl. Body temperature was maintained by means of a
heated operating table and an overhead warming lamp. An
internal carotid artery was cannulated with nylon tubing
(Portex 800/200/100) filled with heparin (7,000 units/ml),
and connected to a Devices pressure transducer for
measuring the arterial blood pressure on a Devices pen
recorder. A wing vein was cannulated with a medical
vinyl tubing (v-3) (Bolab Inc., U.S.A.) for the
administration of drugs. In each preparation,
noradrenaline acid tartarate was given intravenously at
doses increasing from 0.015 to 4.0 yg/Kg in geometric
progression. Tyramine HC1 (20-1280 yg/Kg) was given
following the same protocol. In other preparations
5-hydroxytryptamine creatinine sulphate (0.25-2.0 yg/Kg),
histamine dihydrochloride (1.6-12.8 yg/Kg) and
tryptamine HC1 (5-40 yg/Kg) were injected intravenously
and the depressor responses recorded. All the doses,
in a volume not exceeding 1 ml, were injected at 5 minute
intervals and washed into the circulation with 0.9% w/v
aqueous NaCl (1 ml).
In some further experiments tyramine was given
intraduodenally in anaesthetized preparations of
cockerels (9-10 weeks). A longitudinal incision was
made in the right abdomen 2.5 cm from the midline and
the ascending or descending duodenum opened for the
insersion of a catheter with its tip pointing distally.
Tyramine HC1 was injected intraduodenally at a dose of
5 mg/Kg and further doses were given when the blood
pressure had returned to the control level.
Measurement of feed intake and growth of birds
Before starting a feed trial, the birds were
distributed at random into experimental groups, provided
ad libitum with food and water and left for 4-7 days for
acclimitization to the "new" surroundings. The birds
and their feed intake were weighed daily during the
acclimitization period to accustom them to handling and
to ensure that a normal pattern of feeding and growth had
been attained. A top pan balance (AVERY), measuring to
the nearest gramme, was used.
To achieve a reasonable degree of accuracy in measur¬
ing the feed intake of birds, food was given in different
containers according to the size of the birds, viz. in
experiments where chicks, turkey poults or ducklings were
used, food was given in small bowls (12 cm. in diameter)
covered with wire mesh to prevent spillage associated with
pecking activity and direct contact with the birds. When
chickens (8 weeks or older) were used, the food was given
in troughs with edges turned inwards to minimize spillage.
The container was weighed daily, before and after
replenishment with food.
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Measurement of blood lactate and pyruvate
The enzymatic method of Marbach & Weil (1967) was
used to measure the concentrations of lactate and pyruvate
in blood.
Principle of the method:-
In the presence of nicotine adenine dinucelotide
(NAD+), lactic dehydrogenase (LD) will oxidize lactate to
pyruvate. The reduced form of nicotine adenine
dinucelotide (NADH) produced in the reaction may be
measured spectrophotometrically at 340 nra, and this serves
as a measure of the lactate concentration.
, LD, pH 9.0 to 9.6 „ , TT+Lactate + NAD ^ pyruvate + NADH + H
At pH 9.0 to 9.6 and in the presence of NAD+ and hydrazine
(to trap pyruvate), the equilibrium of the above reaction
favours the oxidation of lactate.
The reaction involved in the determination of pyruvate
is essentially the reverse of the reaction used in the
lactate procedure.
pyruvate + NADH + H+ ■. LD r PH •5 > lactate + NAD+
At pH 7.5, the equilibrium constant of the above reaction
favours the formation of lactate.
Blood collection and deproteinization:-
About 1 ml of blood was collected from a wing vein
by means of a heparinized syringe fitted with a 21 G
needle, and delivered as quickly as possible into a
chilled tared centrifuge tube containing 5% w/v
metaphosphoric acid (.3 ml) . The tubes were stoppered
and the contents mixed quickly by inverting 4 times.
The samples were allowed to stand for 5 minutes at room
temperature before being reweighed and centrifuged at 900 g
for 30 minutes at 5°C.
Lactate determination:-
An aliquot of supernatant (0.1 ml) was
mixed with glycine-hydrazine buffer, pH 9.0 (2 ml),
0.3% w/v LDH in 0.85% w/v NaCl (0.03 ml) and 0.027 M NAD
(0.2 ml) in a 1 cm cuvette, and left for 14 minutes at
room temperature before measuring the absorbence of the
mixture at 340 nm. A standard and a blank were also
prepared in which the deproteinized blood was replaced
with l.OmM lactate in 3% w/v metaphosphoric acid (0.1 ml)
or 3% w/v metaphosphoric acid (0.1 ml), respectively.
The concentration of lactate in the sample was obtained
from the expression:
A test - A blank , , , , , ^x standard concentration (mM) x DA standard-A blank
A, absorbance 3^0 >r1rr' -
D, the dilution of the blood sample in the metaphosphoric
.j , . . , weight of blood + (3 x 1.06)acid and is equal to 2 :—r— /n3 -^ weight of blood
pyruvate determination:-
A portion of supernatant (1.0 ml) was mixed with 0.75 M
Tris buffer, pH 7.4 (0.5 ml) and 0.013 M NADH in 1% w/v
sodium bicarbonate (0.03 ml) in a cuvette (1 cm). The
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absorfaance of the mixture was measured at 340 nm, after
setting the spectrophotometer scale to zero with a 1 cm
cuvette containing 0.0002 M potassium dichromate solution
in the light path. Then 0.3% w/v LDH (0.03 ml) was added
and the absorbotnce measured again after exactly 2 minutes.
A standard and a blank were also prepared in which the
deproteinized blood was replaced with 0.05 mM sodium
pyruvate in 3% w/v metaphosphoric acid (1 ml) or 3% w/v
metaphosphoric acid (1.0 ml), respectively. The
concentration of pyruvate in blood was calculated from
the expression
'AA test - AA blank j_ j j ±. • r ~ r>x standard concentration (mM) x DAA standard - AA blank
45.
Measurement of erythrocyte transketoiase activity
Transketolase (TK) is an enzyme found in nearly all
tissues of the body. It has a requirement for Mg++ and
thiamin pyrophosphate (TPP), and the measurement of its
activity in lysed erythrocytes is considered a useful
test of the thiamin status of animals.
TK activity was measured in chicken erythrocytes by
a method described by Brin (1974).
Basis of the method
TK, in conjunction with its required coenzyme TPP
catalyzes two reactions in the pentose phosphate cycle
(PPC).
TK-TPP
ribose-5-phosphate + xylulose-5-phosphate i v sedoheptulose-
7-phosphate+glyceraldehyde-3-phosphate.
TK-TPE
erythrose-5-phosphate + xylulose-5-phosphate , ■ fructose-
6-phosphate+glyceraldehyde-3-phosphate.
In this method the activity of part of the J?pC is
estimated by measuring the rate of conversion of ribose-
5-phosphate into hexose phosphates. If it is assumed that
the TK reactions are rate limiting, then this activity
gives a measure of the activity of TK. The demonstration
of the dependence of the reaction rate on TPP concentration
(figure 25) is an indication that transketolase is the
limiting enzyme in the assay (Brin 1974). The TK reaction
is stopped by deproteinization after a fixed time and a
reaction product determined spectrophotometrically by the
authrone method.
Collection and lysing of erythrocytes
Blood was withdrawn from a wing vein by means of a
heparinized syringe fitted with a 21G needle and put into
a tared centrifuge tube. The blood was spun down in a
refrigerated centrifuge (5°C) at 900 g for 20 minutes
and the plasma discarded. After drying the outside of
the tubes, the cells were weighed and mixed with an
equal volume of distilled water. The specimens were
stored overnight in the frozen state (-20°C) to affect
complete haemolysis.
Incubation procedure
An aliquot of haemolysate (0.5 ml) was pipetted
into 3 tubes for the 'test', 'tissue blank' and 'TPP
effect' measurements. To the 'test' and 'tissue blank'
a saline-phosphate buffer (0.45 ml and 0.65 ml, respect¬
ively) was added, and 0.26 mM TPP in the same buffer
(0.45 ml) was added to the tube for the 'TPP effect'.
The contents of the tubes were mixed and incubated with
shaking in a water bath at 38°C for 30 minutes. Then
the substrate, 0.47 mM ribose-5-phosphate (0.2 ml) was
added with mixing to the 'test' and 'TPP effect' reaction
mixtures. All three tubes were incubated for 60 minutes
at 38°C with shaking before stopping the reaction with
7.5% w/v trichloracetic acid (6 ml) and centrifuging off
the precipitate at 900 g for 20 minutes at 5°C.
The 'anthrone procedure' was employed for the
spectrophotometric estimation of the 'reaction product'.
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Aliquots of the supernatant (1.0 ml) were mixed with
10 ml of anthrone reagent (2.5 mM anthrone and 0.13 M
thiourea in 66% w/v H^SO.) , heated in a boiling water
bath for 10 minutes, cooled for 5 minutes in a cold water
bath and allowed to stand in the dark for 20 minutes.
Aliquots (1.0 ml) of standard glucose solution (0.55 mM
in 0.75% w/v trichloroacetic acid) and reagent blank
(0.75% w/v trichloroacetic acid) were carried through the
'anthrone procedure' described above.
The absorbance (A) of the solutions was read in a
spectrophotometer at a wavelength of 620 nm, with the
reagent blank set at 0. The activity of transketolase
was obtained from the expression:-
The 'TPP effect' which refers to the increase in
transketojase activity iA- a deficient haemolysate due to
the addition of TPP before incubation, expressed as a
percentage of that in the deficient haemolysate without





hmol/ml) - ' ' units/lit:
A
standard
x 60 x i.o x o.5
TPP effect(%) = (Test with TPP) - (Test without TPP) x 10Q
(Test without TPP)
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Estimation of the Oxygen Consumption in Chicken
Tissue Komogenates
The oxygen consumption of tissue homogenates was
estimated manometrically using the Gilson Respirometer,
which is a direct-reading constant pressure instrument that
measures the oxygen consumed by the incubates.
Preparation of tissues
Chickens (aged 9 weeks) were decapitated and the
tissues rapidly removed and homogenized in 0.067 M phosphate
buffer, pH 7.4.
Incubation procedure
Each incubation mixture consisted of homogenate (2 ml)
(equivalent to 100, 200 or 400 mg tissue) and 0.067 M
phosphate buffer, pH 7.4 (2 ml), and was placed in the main
compartment of a reaction flask. A strip of filter paper
soaked in IN KOH (0.3 ml) was placed in the centre well of
the flask to absorb CO2• Flasks were assembled on the
apparatus without stoppers on the side arm and oxygen blown
through for 5 minutes to displace all air in the system. The
flasks were then stoppered ana immersed in water at 37°C with
shaking. When equilibrium was reached (i.e., the level of the
fluid in the u-tubes was absolutely steady when the by-pass
valves between the arms of the u-tubes were turned off), a note
of time was made and the micrometer pistons adjusted so that
the pressure remained constant in the flasks, readings
being taken at 3, 6, 9, 12, 15, 20, 25 and 30 minutes.
th
The oxygen consumption of the tissues at the 20
min was corrected to values under standard temperature
and pressure (S.T.P.) using tables (Scientific Tables,
Geigy) and expressed as yl02/g tissue/min from the
expression :
Volume of oxygen (S.T.P.) x 1000
( )
Weight of tissue (mg) x 20
50.
Estimation of cholesterol concentration in plasma and
adrenals of chickens
The method of Zlatkis, Zak & Boyle (1953) was used
for the estimation of cholesterol in chicken plasma. A
slight modification of this method was adopted for the
estimation of cholesterol concentration in the adrenals as
described by Knobil, Hagney, Wilder & Briggs (1954).
1. Estimation of total plasma cholesterol
Blood was collected from a wing vein in a heparinized
syringe and put into a centrifuge tube. The blood was
spun down at 900 g for 20 minutes at 5°C. An aliquot
of plasma (0.1 ml) was pipetted into a test tube containing
glacial acetic acid (3 ml). A 'colour reagent' (0.1% w/v
ferric chloride in concentrated f^SO^) (2 ml) was then
added with mixing in a rotamixer for 30 seconds. A light
brown colour first appeared which changed to an intense
purple within a minute. The absorbcuice of the solution
was measured spectrophotometrically at a wavelength of
550 nm. Aliquots (0.1, 0.2, 0.3, 0.4 and 0.5 ml) of a
standard cholesterol solution (1 mg/ml in glacial acetic
acid) were made up to 3.1 ml with glacial acetic acid and
water (0.1 ml) and reacted with the 'colour reagent',
and these served as standards in the estimation of plasma
cholesterol concentration. A reagent blank was also
prepared with each batch of analyses, which contained
glacial acetic acid (3 ml), distilled water (0.1 ml) and
the 'colour reagent' (2 ml).
The concentration of cholesterol in plasma was
calculated from the calibration curve (fig. 9) constructed
from the cholesterol standard solutions in each experiment.
2. Estimation of total adrenal cholesterol
Chickens were decapitated and the adrenals rapidly
dissected out, weighed and homogenized in glacial acetic
acid (10 ml). The homogenates were filtered through
Whatman filter paper (No. 1), and an aliquot of the
filtrate (0.5 ml) mixed with glacial acetic acid (3 ml).
The 'colour reagent' (2.5 ml) was then added with mixing
for 30 seconds. The intensity of the resulting purple
colour was measured in a spectrophotometer at 560 nm.
With each batch of analyses, a fresh calibration
curve was constructed, which related the absorbences at
560 nm to amount of cholesterol.
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Estimation of glucose concentration in chicken plasma
Glucose concentration in chicken plasma was estimated
by a modification of the glucose oxidase method (Kuggett &
Nixon, 1957; Trinder, 1969).
Basis of the method
.
, . , ,t ^ glucose oxidase . , TTglucose + 09 + H90 - -5- gluconate + H2°2
h909 + aminophenazone Perox:'-^ase> coloured complex + h90A2W2
Procedure
Blood was withdrawn from a wing vein of chickens (8
weeks old) using a heparinized syringe fitted with a
21 G needle, and spun down at 900 g for 20 minutes at 5°C
to separate plasma. An aliquot of plasma (0.1 ml) was
deproteinized with 0.1 M sodium tung state (2 ml) and
centrifuged at 900 g for 20 minutes at 5°C. A portion
of the supernatant (0.1 ml) was mixed with a 'reagent'
(2 ml) and incubated at 37°C for 30 minutes with shaking.
r
[The 'reagent' contained peroxidase (80 units/mg)/, glucose
oxidase (129,200 units/g) (8.5 mg), phenol (100 mg) and
4-aminophenazone (30 mg), in 100 ml of 0.01 M sodium
phosphate buffer, pH 7.6}-
In each experiment, aliquots (0.1 ml) of glucose
standards (100, 200 and 500 yg/ml) in 0.1 M sodium
tung. state, and blank (0.1 sodium tungestate) , were
also mixed with the 'reagent' (2 ml) and incubated at
37°C for 30 minutes with shaking.
At the end of the incubation period, the red purple
colour was read in a spectrophotometer at a wavelength of
510 nm. The absorbftnce of plasma supernatants were
converted to concentrations of glucose from a calibration
curve of glucose solutions (fig. 10).
Estimation of ascorbic acid concentration in the
adrenal gland
Ascorbic acid was estimated in the adrenal glands of
chickens by the method of Maickel (1960), which depends
on reduction of Fe+++ by ascorbic acid and estimation
of Fe++ as the red-orange, a - a-dipyridyl complex.
The chickens were decapitated and the adrenals
rapidly removed, weighed and homogenized in 5% w/v
trichloroacetic acid (5 ml) with 6 strokes in a glass
homogenizer. The homogenates were centrifuged at
900 g for 5 minutes at 5°C. An aliquot of the supernatant
(1 ml) was transferred to a test tube and mixed with 85%
H^PO^ (0.3 ml), followed by 0.5% w/v aqueous ci-av -dipyridyl
(5.0 ml), and 1% w/v aqueous FeCl^ (1.0 ml). The tubes
were then allowed to stand at room temperature for 10
minutes before reading the absorbeuice of the red-orange
Fe -a-a-dipyridyl complex in a spectrophotometer at
525 nm using water as a zero reference.
A standard solution of ascorbic acid (.25 yg/ml in
5% w/v trichloroacetic acid) was prepared with each
estimation of adrenal ascorbic acid and carried through
the procedure described above and its absorbence was
used in calculating the amount of ascorbic acid in the
adrenal supernatant.
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Measurement of arterial blood pressure in conscious chickens
Pullets aged 17-19 weeks were divided at random into
two groups; one group received an unmedicated (control)
diet, and the other, furazolidone in the feed at a
concentration of 0.04% w/w for 10 days.
Anaesthesia
Inhalation anaesthesia was induced with halothane
5% v/v in oxygen for one minute, and maintained during the
operation by halothane 2% v/v. The anaesthetic was
delivered from a vaporizer (Fluote 3) at a rate of 500
ml/min through a narrow polyethylene tube inserted in
the trachea.,
Operation
After plucking the feathers from the skull and along
the medial line in the crop region, the anaesthetized bird
was secured on its back and kept warm by an overhead lamp
and a heating table. A longitudinal incision was made
along the medial line and the muscles were separated to
expose the internal carotid arteries. A carotid artery
was cannulated with a nylon catheter (Portex, 800/200/1001
filled with heparin (7,000 i.u./ml) for measuring blood
pressure. Using a metal probe the catheter was drawn up
the neck under the skin and exteriorized near the base of
the skull. A sawn-off syringe needle (25G) was inserted
at the end of the exteriorized catheter and a catheter
adaptor fitted into the needle hub.
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Post-operative care
The chickens were conscious within 10 minutes of
stopping the anaesthesia and were kept in draught-free
ventillated 'recovery' boxes for at least 3 hours before
measuring the arterial blood pressure.
Measurement of arterial blood pressure in conscious
chickens
Each bird was placed in a ventillated wooden box
with the minimum of excitement and was left undisturbed
for 30 minutes before recording blood pressure. The
exteriorized cannula was connected to a blood pressure
transducer which was attached to a pressure amplifier
and a pen recorder (Devices 3552). The mean arterial
blood pressure was obtained from 3-4 blood pressure
recordings made at 30 minute intervals.
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Determination of packed cell volume and haemoglobin
content of chicken blood
Packed cell volume (PCV)
PCV was measured in chicken blood by the micro-
haematocrit method as described by Dacie & Lewis (1975).
Blood was collected from a wing vein in a heparinized
syringe, and mixed in a centrifuge tube. The blood was
introduced to the microhaematocrit capillary tubes (75 mm x
1.0 mm) by capillarity, leaving at least 15 mm unfilled.
The tip of the capillary was sealed with plasticine and
the tubes placed in a microhaematocrit centrifuge (Hawksley,
England) and spun down at 12,000 g for 5 minutes. After
centrifugation, the capillary tube was placed in a reading
device (Hawksely Reader, Cat. No. A.802), and PCV read
directly from the scale.
Haemoglobin (Hb) content
The cyanomethaemoglobin (HiCN) method described by
Dacie & Lewis (1975) was employed for the estimation of
Hb in chicken blood. In this method blood is diluted with
a solution containing potassium ferricyanide and potassium
cyanide to convert Hb to HiCN. The absorb<vnce of HiCN
is then measured in a spectrophotometer.
The cyanide reagent used in the present experiments
consisted of potassium ferricyanide (200 mg) and
potassium cyanide C50 mg) dissolved in 1 litre of 0.1 M
phosphate buffer solution, pH 7.2, the buffer being
intended to overcome the formation of a red precipitate
from the fowl's blood CBeuving & Teunis (1974)).
Chicken blood (20 yl) was added to the cyanide
reagent (5 ml) and mixed with a rotamixer. The
colourless precipitate formed was centrifuged down
(900 g for 5 minutes at 5°C) immediately after addition
of the blood to the cyanide reagent. The supernatant
was left for 10 minutes at room temperature and its
absorba.nce was read in a spectrophotometer at a
wavelength of 540nm, against a blank of cyanide reagent.
A standard solution of HiCN was also read against the
blank. Haemoglobin content of the blood (g/100 ml)
was obtained from the expression:-
absorbence of test sample
absorbence of standard
concentration of standard (mg/100 ml) x dilution factor
1000
59.
Determination of the Activity of Aspartate Transaminase in
Chicken Plasma
The activity of aspartate transaminase (AST, EC 2.6.1.1)
was determined in chicken plasma by the method described by
Wilkinson, Baron, Moss & Walker (1972), which measures the
rate at which absorba,nce at 340 nm decreases as NADH is
oxidized to NAD.
Principle of the method
The reactions involved in the determination of AST
activity are as follows :
AST
aspartate + 2-oxoglutarate glutamate + oxaloacetate (1)
malate
dehydrogenase +
oxaloacetate + NADE + H vmaiatp + NAD (2)
The oxaloacetate produced by the aspartate transaminase
serves as substrate for malate dehydrogenase by which it is
reduced to malate in the presence of NADH, which is
simultaneously oxidized. NADH has an absorbance peak at
340 nm which is not shown by the oxidized form, and the
decrease in absorbence at this wavelength provides a means
for the measurement of the aspartate transaminase activity.
Procedure
Blood was withdrawn from a wing vein by means of a
heparinized syringe fitted with a 21 G needle and spun down
at 300 g in a refrigerated centrifuge (5°C) for 20 min to
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separate plasma. An aliquot of plasma (0.2 ml) was added
with mixing to 0.1 M phosphate buffer, pH 7.2 (1.3 ml),
0.375 M L-aspartate (1.0 ml), 3.53 mM NADH (0.2 ml) and
malate dehydrogenase (5 u/ml) (0.1 ml), and the mixture
incubated for 15 min at 25°C. The mixture was transferred
to a cuvette (1 cm) and the reaction started by the addition
of 0.1 M 2-oxt)glutarate (0.2 ml) followed by mixing. The
decrease in absorbAnce was then measured at 340 nm every
minute for a period of ten minutes. For the purpose of
calculation the readings obtained at the first three minutes
were excluded (as the reaction does not obey zero order
kinetics during this period).
The rate of change in absorb^nce/minute was measured
(AA/min) and the aspartate transaminase activity was cal¬
culated in u/1 from the expression :
enzyme activity = AA/min x 2400 u/1
I
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Statistical analysis of results
When three or more observations were made, the
values reported in the text, tables and figures are the
means with standard errors. The significance of the
difference between the means was estimated by the t-test
and probability CP) values are given. A value of
P < 0.05 is regarded as significant. Regression lines
were calculated by the method of least squares.
Chapter I
The effect of furazolidone on MAO activity
Results
The effect of age on MAO activity in the chicken
Many workers have shown that the activity of MAO in
tissues of avian species increases with age (Ignarro &
Schiedeman, 1968; Watts, Mendes, Reilly & Krop, 1969;
Fowler & Callingham, 1977). At hatching, the activity
of MAO in the brains of chicks, ducklings and pigeons
has been shown by Watts et al (.1969) to be about 60%,
90% and 34%, of the adult level, respectively. An
experiment was conducted in which MAO activity was
measured in organs of day-old and 8-weeks old chickens.
The results of this experiment (table 3 )showed that the
activity of the enzyme in the duodenal mucosa, liver and
heart of day-old chicks was significantly lower than in
8 weeks old chickens (P < 0.02 - < 0.001). No signif¬
icant difference was found in the activity of MAO in the
brains of chickens at these ages (P > 0.2).
In some of the present experiments, it was necessary
to use birds at one particular age in order to avoid age
variation in MAO activity.
The effect of furazolidone feeding on MAO activity in
chickens, ducklings and turkey poults
When furazolidone was given in the food at a concen¬
tration of 0.04% w/w for 10 days, the activity of MAO was
reduced significantly in the duodenal mucosa, heart and
brains of chickens, ducklings and turkey poults. Only in
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the duckling was a significant inhibition of MAO activity
found in the liver (P < 0.01) (table 4). These experim¬
ents were repeated twice with chickens and once with
ducklings and similar results were obtained.
In another experiment, the recovery of the enzyme
activity after discontinuing the medicated feed was
investigated in the chicken. This experiment confirmed
the effect of feeding furazolidone on MAO activity, which
was inhibited in the duodenal mucosa (P < 0.001), heart
(P < 0.02) and brain (0.02) and not in liver (P > 0.1)
(fig.il). Seven days after discontinuing furazolidone
in the feed a significant recovery of MAO activity was
only evident in the duodenal mucosa (P < 0.002). Fourteen
days after discontinuing the drug, the recovery of MAO
activity was complete in each organ, there being no
significant difference from the controls (P > 0.1 for each
organ).
The distribution of MAO activity in the mucosa of the
alimentary tract of chickens aged 10 weeks is shown in
fig. 12. A very high activity was found in all parts of
the alimentary mucosa, except in the oesophagus, and even
here the activity was of the same order as that found in
the liver and brain of birds aged 8 weeks. Although MAO
activity in chicken organs increases with age, a comparison
between birds aged 8 and 10 weeks seems valid as the
activity in the duodenal mucosa did not differ significantly
at these ages (P > 0.1).
The inhibition of MAO activity in the alimentary
mucosa of the chicken (except that in the rectum) follow¬
ing the treatment with furazolidone at the therapeutic
dose (0.04% w/w in the feed for 10 days) was more than
that in the heart, brain or liver (fig. 13). The enzyme
inhibition was most marked in the caecal mucosa (P < 0.02 -
<0.001 compared with other organs), and least in the liver
where none was found (P > 0.1).
The effect 'of furazolidone by crop tube or intramuscular
injection on MAO activity in chickens.
Furazolidone was administered to chickens at a dose
of 200 mg/kg body weight, which is about half the reported
LD^0 in this species (Radchuck, 1965). The drug admin¬
istered by crop tube inhibited MAO activity in the chicken
liver as well as in duodenal mucosa, heart and brain
(table 5). The time course of inhibition was different
in various organs, however, being maximal in the liver 12
hours after drug administration and in the duodenal mucosa
and brain after 24 hours. In contrast, furazolidone
injected intramuscularly did not affect MAO activity in any
of the organs studied (P >0.1 for each organ, 6 birds)
(fig. 14).
Potency of furazolidone as an MAO inhibitor in chicks,
ducklings and turkey poults
MAO activity was measured in chicks, ducklings and
turkey poults aged 2-12 days, 24 hours after the
administration of graded doses of furazolidone by crop
tube.
As shown in fig.15/ there was no species difference
between chickens and ducklings in the potency of
furazolidone as an MAD inhibitor in the liver, heart and
brain. Although furazolidone inhibited MAO activity in
the duodenum in the duckling more than in the chicken in
this experiment, this observation seems of little
significance as it was not confirmed in other experiments
(c table 6 & table 7).
A comparison of the potency of furazolidone as an iMAO
inhibitor in the turkey poult and chicken (fig.16) showed
no species difference in the duodenum, liver or brain.
However, in the heart, furazolidone was more potent as an
MAO inhibitor in the turkey poult than in chickens. This
apparent species difference was not observed when
furazolidone was given to the birds in the feed (0.04% w/w,
10 days) when cardiac MAO was inhibited to similar extent
in the two species (table 4). Thus further experiments
are required to determine whether or not this effect is
repeatable.
Influence of neomycin on the inhibition of MAO by
furazolidone in chickens and ducklings
Chickens (8 weeks old) were given neomycin, either
20 mg by intramuscular injection or 200 mg by crop tube
twice daily for 5 days before the MAO estimation.
Furazolidone (200 mg/kg) was administered by crop tube
to saline- and neomycin-treated birds 24 hours before the
enzyme estimation. Neomycin did not affect MAO activity
and the values obtained from chickens pretreated with
saline or neomycin and given acacia mucilage (crop tube)
were pooled and used as controls. As shown in table o,
furazolidone administered by crop tube inhibited MAO
activity in each organ as before (P < 0.001), and pretreat-
ment with neomycin by the intramuscular route did not
affect the MAO inhibition (P > 0.1). On the other hand,
pretreatment with neomycin by crop tube significantly
reduced the MAO inhibiting action of furazolidone in each
organ (P < 0.01 to < 0.001). Following oral administration
of neomycin and furazolidone (by crop tube) the activity of
MAO was less than the control value in the liver (P < 0.002)
and brain (P < 0.05) but not in the duodenal mucosa (P > 0.1)
and heart (P > 0.05). Thus the suppression of the MAO
inhibiting action of furazolidone by the oral neomycin was
complete in the duodenal mucosa and heart but not in the
liver and brain.
In another experiment, furazolidone and neomycin were
administered by crop tube to ducklings aged 2-8 days, to
see whether or not neomycin would antagonize the action of
furazolidone as an MAO inhibitor in this species. In
neomycin-treated ducklings the furazolidone did not inhibit
MAO activity in the liver (P > 0.05) and brain (P > 0.1)
(table 7 ) , although it did so in the controls (P < 0.01).
Effect of furazolidone on aminopyrine demethylase activity
In two experiments the effect of furazolidone on
aminopyrine demethylase activity in a microsome-rich
supernatant fraction of liver was investigated (table 8).
In one experiment the drug was given in the feed at the
therapeutic dose (0.04% w/w, 10 days) and in the other by
crop tube at a dose of 200 mg/kg 24 hours before the
estimation of the enzyme activity. In both experiments
the activity of aminopyrine demethylase was unaffected by
the drug.
Discussion
Furazolidone administered in the feed at a concentration
of 0.04% w/w for 10 days inhibited MAO activity in the
duodenal mucosa, heart and brain of chickens, ducklings and
turkey poults. Only in ducklings was there a significant
inhibition of the activity of MAO in the liver. MAO is
inhibited by a transformation product of furazolidone
(Stern et al, 1967; Pettinger et al, 1968) and MAO in¬
hibition would be expected at the site of transformation.
As MAO activity was not inhibited in the liver of chickens
and turkey poults, it seems improbable that the transformat¬
ion of furazolidone occurred here. The inhibition of MAO
activity in liver of ducklings treated with furazolidone
(0.04% w/w, 10 days) may indicate that the hepatic clearance
of the active metabolite is less efficient in this species.
The very low activity of mixed function oxidase in the duck
liver (Bartlet & Kirinya, 1976) lends support to this
suggestion.
Following withdrawal of medication from chickens, the
enzyme activity recovered more promptly in the duodenal
mucosa than in other organs. The recovery of activity
may be due to synthesis of new enzyme, as dialysis does
not restore activity to MAO inhibited by furazolidone
(Stern et al, 1967).
Furazolidone administered to chickens by crop tube
inhibited the activity of MAO in the duodenal mucosa,
liver, heart and brain. Thus, in the chicken, furazol¬
idone given as a bolus inhibited the hepatic enzyme,
although it did not do so when fed continuously. In the
hepatocytes, the furazolidone metabolite may inhibit
mitochondrial MAO, or it may be metabolized further and/or
excreted with bile. The present observation suggests that
the clearance of the metabolite was insufficient to protect
hepatic MAO from inhibition when the drug was given as a
bolus (200 mg/kg), but was sufficient when it was given as
a feed additive (0.04% w/w, 10 days). In chickens,
following furazolidone by crop tube, a maximum inhibition
of MAO in the liver was found after 12 hours and in other
organs after 24 hours. This observation suggests that the
hepatic clearance of the furazolidone metabolite resulted
in a briefer inhibition of MAO in the liver than elsewhere.
Furazolidone administered to chickens by intramuscular
injection did not affect the activity of MAO in any of the
organs studied. This observation suggests that conversion
of the drug to an MAO inhibitor did not occur in the
bird's tissues. However, this finding may not extend
to other species as furazolidone given by intravenous or
intraperitoneal injection, is reported to inhibit MAO
in the rat (Stern et al, 1967).
The alimentary flora might have produced the metabolite
which inhibited MAO activity. To test this hypothesis,
MAO activity was measured in different parts of the
alimentary tract in chickens given furazolidone at a
concentration of 0.04% w/w for 10 days. The inhibition
of MAO activity was most marked in the rectal caeca and
crop, where the alimentary flora is most abundant in the
chicken (Jayne-Williams & Fuller, 1971). Further support
for the hypothesis was obtained from the experiment
in which furazolidone was given to chickens by crop tube
after suppressing the alimentary flora with neomycin.
Pretreatment with neomycin by crop tube antagonized the
action of furazolidone on MAO activity, but neomycin
injected intramuscularly at one-tenth of the oral dose
did not do so. Less than 10% of neomycin is absorbed
from the alimentary tract (Waksman, 1953; Freyburger &
Johnson, 1956), so in these experiments absorbed neomycin
could not have influenced the actions of furazolidone on
MAO activity. The inhibition of MAO activity by
furazolidone was suppressed by unabsorbed neomycin, which
supports the hypothesis that the alimentary flora
transform furazolidone to an active metabolite which is
subsequently responsible for the inhibition of MAO activities
in other organs. In ducklings, the inhibition of MAO
activity following the administration of furazolidone by
crop tube was antagonized by neomycin given by the same
route. This observation suggests that the alimentary
microflora transformed furazolidone to an MAO inhibitor in
ducklings, as in the chicken.
Furazolidone (administered by crop tube) was about
equipotent in chickens, ducklings and turkey poults as an
inhibitor of MAO activity. Thus in these species, the
alimentary microflora seemed equally active in transforming
furazolidone to an MAO inhibitor.
Many drugs inhibit both MAO and mixed function oxidase
(Kato, Takanaka & Shoji, 1969). Aminopyrine demethylase
activity' in the chicken liver, however, was unaffected by
furazolidone treatment (0.04% w/w, 10 days, or 200 mg/kg
by crop tube). Thus furazolidone at the recommended
therapeutic dose would not be expected to potentiate the
actions of other drugs metabolized by mixed function oxidase.
Chapter II
The pharmacological consequences of MAO inhibition by
furazolidone
Having established that the avian MAO activity was
inhibited by furazolidone, the next consideration was
whether or not it was sufficient to give rise to
pharmacological effects. It is known that the inhibition
of MAO activity may lead to an increase in the amounts of
tissue monoamines (Spector, 1963), potentiate some of
their actions (Goldberg & Sjoerdsma, 1959), and increase
the urinary excretion of unmetabolized monoamines
(Brunjes, Haywood & Maronde, 1963).
In the following experiments, the effect of
furazolidone on the amounts of monoamines in the brain of
chickens and ducklings, and on the vasopressor and
vasodepressor actions of some amines have been investigated.
Results
The effect of furazolidone (0.04% w/w, 10 days) on the
amounts of 5-HT, adrenaline and noradrenaline in the brain
Furazolidone was given in the feed to chicks and
ducklings (aged 2 days at the commencement of the exper¬
iment) and the amounts of 5-HT, adrenaline and noradrenaline
measured in the brains of control and treated birds. The
results of this experiment (Table 9 ) show that following
furazolidone treatment the amount of 5-HT in the brain was
increased significantly in both chicks (P < 0.001) and
ducklings (P < 0.05), whereas the amounts of adrenaline
and noradrenaline were unaffected.
The effect of furazolidone on the vasopressor actions of
noradrenaline and tyramine
The regressions of the vasopressor responses upon
dose for noradrenaline and tyramine injected intravenously
in anaesthetized preparations of chickens are shown in
fig. 17. The response to noradrenaline in preparations
made from chickens given furazolidone in the feed (0.04%
w/w, 10 days) were the same as those in control preparat¬
ions. In contrast, pretreatment with furazolidone at the
therapeutic dose potentiated the vasopressor action of
tyramine 2.5-5 fold (P < 0.01).
Tyramine hydrochloride (5 mg/kg and above) injected
intraduodenally in anaesthetized preparations of chickens
produced a prolonged rise in arterial blood pressure, the
response reaching a maximum in about 5 minutes and subsid¬
ing over 6-9 minutes (fig. 18 ). The vasopressor action
of intraduodenal tyramine was potentiated about 5-fold in
preparations made from chickens treated with furazolidone
(0.04% w/w, 10 days) (Table 10), the action of 5 mg/kg of
the drug in the furazolidone-treated preparations not
being significantly different (P > 0.1) from 25 mg/kg in
the controls.
The effect of furazolidone (0.04% w/w, 10 days) on the
vasodepressor actions of 5-HT, histamine and tryptamine
5-HT, histamine and tryptamine were injected intra-
venously into anaesthetized preparations of control and
furazolidone-treated chickens, and the vasodepressor
responses recorded. There was no significant difference
between the vasodepressor actions of the amines in the
control and the drug-treated preparations (fig. 19)
(P > 0.1) .
Discussion
Furazolidone, given in the feed at the therapeutic
dose for galliformes increased the amount of 5-HT in
the brains of chickens and ducklings. The increase in
5-HT was selective, as the amounts of adrenaline and
noradrenaline in the brains were unaffected by the treat¬
ment. This finding is not atypical, e.g. administration
of an MAO inhibitor to the rabbit may produce a selective
increase in the amount of 5-HT in the brain (Spector,
Shore & Brodie, 1960). In all probability treatment with
furazolidone at a higher dose would have increased the
amount of catecholamines in avian brain. Indeed, the
administration of furazolidone (500 mg/kg) to the rat
produced an increase of both 5-HT and noradrenaline in
the brain (Palm, Magnus, Grobecker & Jonsson, 1967). The
behavioural stimulation noted in ducks and pigs given
furazolidone (Lucas, 1956; Borland, 1979), was most
probably due to the increased amount of monoamines in the
brains of the affected animals.
Furazolidone given in the feed potentiated the
vasopressor action of tyramine administered intravenously.
In vivo, tyramine is metabolized by oxidative deamination
whereas noradrenaline is mostly inactivated by other
routes, and the present findings indicate that following
furazolidone therapy the inhibition of MAO activity in
the vasculature and the heart was sufficient to potentiate
the action of tyramine in the systemic circulation.
Tyramine (5 mg/kg and above) injected into the
duodenum produced a vasopressor response in control prepar¬
ations, indicating that a significant amount of the amine
was absorbed. Pretreatment of the birds with furazolidone
(0.04% w/w, 10 days) potentiated the vasopressor action of
tyramine about five-fold, regardless of whether the amine
was given intravenously or intraduodenally. Thus in the
chicken, furazolidone at the therapeutic dose seemed to
have little influence on the absorption of tyramine into
the systemic circulation from the gut. Although more of
the tyramine may have been absorbed into the portal
circulation from the duodenum when the MAO activity in the
alimentary tract was inhibited, it seems that the amount
reaching the systemic circulation was not affected signif¬
icantly, probably because the hepatic MAO was not inhibited
in the furazolidone-treated preparations.
The vasodepressor actions of histamine, 5-HT and
tryptamine were not significantly affected by the furazol¬
idone treatment. The reason for this is not clear, but
the drug is known to inhibit the activities of both MAO
and diamine oxidase (DAO) (Palm & Magnus, 1968), and in the
present experiments, it seems that the inhibition of
these enzymes in the heart, blood and vasculature was
not sufficient to potentiate the actions of the injected
amines. An alternative explanation for the lack of
potentiation of histamine and 5-HT is that histamine is
only partly metabolized by DAO and that its fate depends
above all on the activity of imidazole-N-methyl transfer¬
ase. Although injected 5-HT is mostly metabolized by
MAO, a considerable proportion of the endogenous amine is
cleared by conjugation with glucoronic acid (Bartlet, 1971)
and it is possible that following MAO inhibition by




Anorexia in poultry given furazolidone
A marked reduction in the growth of birds treated
with furazolidone (0.04% w/w, 10 days) , was noted in the
previous experiments, and the nature of the phenomenon
is examined here.
In the description of the following experiments the
word "furazolidone" indicates that the drug was given in
the feed at a concentration of 0.04% w/w for 10 days,
and the age of the birds on the first day of the feeding
is given in parenthesis.
Results
The effect of furazolidone on the feed intake and growth
of poultry kept in groups (3-4 birds)
The furazolidone was given to chickens (7^ weeks)
and the feed intake and growth measured daily. In the
treated birds the feed intake was significantly less
than that in the controls (P < 0.05) (fig.20), and the
growth (with respect to the initial body weight and feed
consumption) was also reduced (P < 0.001 - <0.002). The
feed intake and growth in four groups of ducklings (4 days)
were similarly inhibited by furazolidone (P < 0.05 -<0.02)
(fig. 2d .
In one group of turkey poults (4 days) furazolidone
reduced the feed intake to 2.1 (kg)/kg body weight/10 days,
while the control group consumed 2.9 (kg)/kg body weight/
10 days. The growth of the treated birds, 754.5 ± 90.2
(g)/kg body weight/10 days (n = 6 birds), was less than that
in the controls, 1310.3 ± 101.2 (g)/kg body weight/10 days
(n = 6) (P < 0.01) .
The feed intake and growth in chickens housed individually
and fed ad. libitum
In order to proceed to a pair-feeding experiment, it
was necessary to obtain data on the feed intake and growth
of birds housed individually. It was noted that the feed
intake and growth of the individually-housed chickens was
less than that in the grouped birds. This is in accord
with other workers' findings (Tolman, 1964; Tolman &
Wilson, 1965) that a chicken eats more in the presence of
a companion than in isolation.
Chickens weeks) were caged singly and given
furazolidone, the controls receiving an unmedicated diet.
In the treated birds growth was less than in the controls
(P < 0.01) on days 6 - 10 of the experiment (fig.21).
No significant difference, however, was found between the
cumulative feed intakes of the control and treated birds.
Growth in pair-fed chickens
Chickens of the same age as those used in the previous
experiment were housed individually and their growth record¬
ed. The birds were divided into two groups and given
restricted diets of unmedicated food, the amount being
equivalent to that consumed ad libitum by the control and
the furazolidone-treated birds in the previous experiment.
The two groups of pair-fed chickens grew at about the
same rate on days 1 - 4 of the experiment (P > 0.05 - 0.1)
(fig.~2~2). However, on days 5 to 10, the chickens
pair-fed with furazolidone-treated birds grew significantly
less than those pair-fed with control birds (P < 0.05 -
<0.02).
The growth of the pair-fed birds is compared with
that of those fed ad libitum in fig. 2-3. There was no
significant difference in growth between the birds fed
ad libitum with control diet and their pair-fed counter¬
parts CP > 0.1) Cfig.23.A) . Moreover, the growth of
chickens fed ad libitum with furazolidone was not signif¬
icantly different CP > 0.1) from that in pair-fed birds
on control diet Cfig.2'3B) . However, the pair-fed birds
showed a tendency to grow more than the drug-treated
birds on days 7 to 10 of the experiment, although this
did not reach significance.
The effect of methergoline on the feed intake and growth
of chickens
This experiment examined the effect of methergoline,
a potent and long-lasting antagonist of the central actions
of 5-HT (Beretta, Ferrini & Glasser, 1965; Mawson &
Whittington, 1970), on the feed intake and growth of
chickens (7\ weeks) kept in groups and given furazolidone.
The methergoline was dissolved in 2% w/v aqueous ascorbic
acid and injected intramuscularly at a dose of 1 mg/kg
twice daily for the 10 days of the experiment.
Methergoline produced no significant improvement in
the feed intake or the growth of chickens (P > 0.1) (table 11)
Discussion
The influence of furazolidone on the growth of
chickens was studied as early as 1953, when it was shown
that feeding the drug at a low concentration (0.006% w/w
for 10 weeks) did not affect the growth of chickens kept
under hygienic conditions (Jacobs et al, 1953). There¬
after, several workers (Cooper & Skulski, 1956; McDonald
& Beilharz, 1961; Jensen et al, 1975; Ehlhardt, 1975)
found that growth in chickens was reduced when furazolidone
CO.033% - 0.04% w/w) was given for one to four weeks.
However, in most of these studies the feed intake of the
birds was not measured, and the reduction in growth
produced by the drug was attributed variously to impaired
digestion, absorption or metabolism.
In the present experiments, the reduction in feed
intake in the furazolidone-treated birds did not result
from a distaste for the drug, as it did not start on the
first day of the treatment but took some days to develop.
The growth of the chickens fed ad libitum with
furazolidone was not significantly different from that
of the birds pair-fed with unmedicated food. This
observation suggests that, in the furazolidone-treated
chickens, the reduction in growth was mainly due to the
reduced feed intake. This conclusion is supported by
the significant difference in growth between the chickens
pair-fed with the furazolidone-treated and the control
birds. Thus the reduction in growth in the furazolidone-
treated birds could be fully accounted for by the anorexia.
It seemed that the increase in brain 5-HT in the
furazolidone-treated birds might have given rise to
the anorexia, as 5-HT is known to play a role in the
regulation of feed intake (Blundell, 1977; Blundell &
Latham, 1978). In the rat, methergoline (1 mg/kg; i.p.)
antagonized the anorectic action of m-chloro-phenylpiperazine
(an agonist at the central tryptaminergic receptors)
(Samanin, Mennini, Ferraris, Bendotti, Borsini & Grattis,
1979). In the present experiments, however, methergoline
CI mg/kg, intramuscularly twice daily) did not antagonize
the anorexia significantly in the furazolidone-treated
chickens. Thus it seems unlikely that the anorexia in
the birds was an outcome of the increase in brain 5-HT.
Chapter IV
Effect of furazolidone on the thiamin status of birds
In the rat, the monoamine oxidase (MAO) inhibitors
iproniazid, harmaline and phenylcyclopropylamine
increased the concentrations of pyruvate and lactate in
blood (Gey & Pletscher, 1961). This effect was attrib¬
uted to an inhibition of the metabolism of monoamines,
because it occurred simultaneously with an accumulation
of 5-HT in the brain, and because 5-HT and noradrenaline
given subcutaneously increased pyruvate and lactate in
blood. However, doubt is cast upon the above explanation
by the observation in man that nitrofurazone, which does
not inhibit MAO (Quiring & Palm, 1970), also produced an
increase in blood pyruvate (Knight, 1959; Robertson,
1959) .
In the turkey, the concentrations of pyruvate and
lactate in blood were increased after treatment with
furazolidone (0.04% w/w, 28 days) (Staley et al, 1978) ,
and the drug produced a cardiomyopathy which resembled
that occurring in thiamin deficiency in man (beriberi).
A rise in blood pyruvate and lactate can also be a sign
of thiamin deficiency (Horwitt & Kreisler, 1949).
In the present experiments furazolidone produced
anorexia, another common sign of thiamin deficiency.
Thus it seemed of interest to determine the thiamin
status of birds treated with furazolidone. In all the
following experiments the drug was given in the feed at
a concentration of 0.04% w/w for 10 days, and the age
of the birds on the 10th day of the feeding is given in
parenthesis.
Results
Effect of furazolidone on the concentrations of pyruvate
and lactate in the blood of poultry
The concentrations of pyruvate and lactate were
measured in the blood of chickens (9 weeks), ducklings
(2 weeks) and turkey poults (2 weeks) given furazolidone.
The drug produced a significant increase (P < 0.05-<0.001)
in the concentrations of pyruvate and lactate in the blood
of the three species (fig. 24).
Influence of thiamin on the concentrations of pyruvate
and lactate in furazolidone-treated chickens
In this experiment with chickens (9 weeks), thiamin
hydrochloride was injected intramuscularly at a dose of
84 yg/kg (twice daily, at 9.00 a.m. and 4.45 p.m.)
during the administration of furazolidone. The dose
of thiamin was slightly above the daily requirement of
this vitamin for 1\ weeks old chickens of light breed
(see table 11 in Nutrient Requirements of Poultry,
Anonymous, 1971). The thiamin did not produce a
significant reduction in the concentrations of pyruvate
and lactate in the blood of chickens given furazolidone
(P > 0.05) (table 12). Moreover, furazolidone still
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raised the concentration of pyruvate in chickens
injected with thiamin (P < 0.01), although the lactate
concentration was not increased significantly (P > 0.05).
Effect of furazolidone on the activity of transketolase (TK)
and the thiamin pyrophosphate (TPP) effect in chicken
haemolysates
The activity of TK in the haemolysates was not
significantly affected following administration of
furazolidone to the chicken. On the other hand, the
increase in TK activity produced upon addition of TPP
to the haemolysates (TPP effect) was significantly
greater in preparations from furazolidone-fed chickens
than in controls (P < 0.02) (fig. 25).
Influence of thiamin on TK activity and the TPP effect
in chickens given furazolidone
Although thiamin given intramuscularly at the above
dose did not affect the TK activity in either furazolidone-
treated or control chickens (P > 0.1), it produced a
significant decrease (P < 0.05) in the TPP effect in
chickens given furazolidone (table 13). The thiamin did
not reduce the TPP effect to the normal value, however,
as it was still higher in birds treated with furazolidone
and thiamin than in those given thiamin only (P < 0.001).
Effect of thiamin on the anorexia produced by furazolidone
In one experiment, the chickens were 8 weeks old at
the start of feeding, and in another 11 weeks. Because
of the difference in feed intake and growth of the birds
at these ages, the data from the two experiments are
presented separately (table 14 ). The growth of the
control and the furazolidone-treated chickens was not
significantly affected (P > 0.1) by thiamin, nor was their
feed intake.
Effect of furazolidone on oxygen consumption of chicken
tissues
The oxygen consumption of the duodenal mucosa,
liver, heart and brain from control and furazolidone-fed
chickens (9 weeks) has been measured ( fig. 26). in
the homogenates of heart prepared from drug-treated birds,
the oxygen consumption was significantly greater than
that in control preparations (P < 0.02 for 200 and 400 mg
tissue). However, furazolidone did not produce any
significant change in the oxygen consumption of the other
organs, with the exception of liver (400 mg) where it was
reduced (P < 0.001).
Effect of thiamin on MAO activity in chickens treated
with furazolidone
In the chicken, thiamin did not affect the MAO
inhibitory action of furazolidone in the caecal mucosa,
heart and brain (P > 0.1) (table 15).
Discussion
In thiamin deficiency, the concentrations of pyruvate
and lactate are increased in the blood (Horwitt &
Kreisler, 1949), and in haemolysates there is a decrease
in the TK activity and an increase in the TPP effect
(Brin, 1961^) 11960; Sauberlich, 1967). According to
Brin (.1974) a TPP effect of 15-24% suggests a borderline
deficiency of thiamin, and an acute thiamin deficiency
(.usually with clinical signs) is indicated by a TPP
effect greater than 25%. These biochemical indices
were useful in assessing the thiamin status of chickens
given furazolidone.
In the present experiments, furazolidone increased
the TPP effect and the concentrations of pyruvate and
lactate in blood, and produced anorexia. The magnitude
of the TPP effect in the furazolidone-treated chickens
suggested that the drug had produced a borderline
deficiency of thiamin. Although only anorexia and
blood pyruvate and lactate concentrations were measured
in turkey poults and ducklings, the drug seemed to
produce a similar effect in these species.
Thiamin was given to furazolidone-treated chickens
to try to reverse the signs of its possible deficiency
(.the anorexia, the increased concentrations of blood
pyruvate and lactate, and increased TPP effect). The
vitamin did not counteract significantly either the
anorexia or the increase in blood pyruvate and lactate
concentrations, although it produced some reduction
in the TPP effect. It should be mentioned that in the
chicken, thiamin at 2/3rd the present dose was effective
in abolishing the adverse effects of amprolium, a known
thiamin antagonist CPolin, Wynosky & Porter, 1962).
Thus in the present experiments, the failure of thiamin
to counteract the signs of its possible deficiency seems
to suggest that furazolidone may have interfered with
its utilization.
There are, however, some observations that seem
inconsistent with the proposition that furazolidone
induced a thiamin deficiency in the birds. It is known
that the oxygen consumption of brain tissue from thiamin-
deficient pigeons is reduced (Banga, Ochoa & Peters, 1939).
Yet, in the present experiments, treatment of chickens
with furazolidone did not affect the oxygen consumption of
brain homogenates. Indeed, a significant increase was
found in the oxygen consumption of the heart following the
administration of furazolidone. This phenomenon is not
understood, but could be due to the accumulation of
pyruvate and lactate, as these substrates are known to be
an important source of energy in the heart (Bing, 1955;
Opie, 1969). The increase in the hepatic and cardiac
glycogen concentrations in turkeys given furazolidone
CCzarnecki et al, 1974) also seems inexplicable in terms
of thiamin deficiency.
The MAO inhibitory action of furazolidone was
unaffected by thiamin. As the dose of the vitamin was
ineffective in reversing signs of its possible deficiency,
one cannot reach a conclusion as to whether or not the
signs of thiamin deficiency and the inhibition of MAO
were related phenomena. It has been reported, however,
that MAO activity in thiamin-deficient rats was lower than
in controls, and that it could be restored to a normal




Effect of Furazolidone on the Adrenal Glands of the Chicken
According to Palm, Magnus, Grobecker & Johnsson (1967),
administration of furazolidone (500 mg/Kg, orally) to the rat
reduced the amount of catecholamines in the adrenal medulla
by about 30%. In the chicken, furazolidone (given in the
feed at a concentration of 0.04% w/w for one week or
0.01% w/w three weeks) has been reported to increase the
level of corticosterone* in plasma (Sidorov & Luders, 1971)
and it was suggested that the drug produced a non-specific
"stressor" effect.
An apparent increase in the weight of the adrenal gland
in chickens, treated with furazolidone (0.04% w/w, 10 days)
led us to examine the effect of the drug on this organ.
The amount of catecholamines in the adrenal medulla and
several parameters of adreno-cortical function were measured.
In all the following experiments furazolidone was given to
the chickens in the feed at a concentration of 0.04% w/w
for 10 days.
* It should be mentioned that the estimation of corti¬
costerone in this report is of dubious validity, as
the fluorimetric method used was shown subsequently to
be neither specific nor accurate in measuring avian
corticosterone (Freeman, Manning & Flack, 1979).
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Results
Influence of furazolidone on the catecholamines in the
adrenal glands
Adrenaline and nor—adrenaline were measured in the
adrenal glands of control and furazolidone-treated cockerels.
The drug did not affect the amount or the concentration of
either amine in the adrenal glands (P > 0.1 in each instance,
table 16) .
Effect of furazolidone on concentrations of ascorbic acid
and cholestrol in the adrenal glands, and cholestrol and
glucose in plasma
Treatment of cockerels with furazolidone produced a
small and statistically insignificant (P > 0.05) reduction
in the concentration of cholestrol in the adrenal glands.
The drug had no effect on the concentrations of ascorbic
acid in the adrenal glands, and cholestrol and glucose in
plasma (P > 0.1 in each instance, table 17) .
Effect of furazolidone on organ weights
The weights of the adrenal glands, heart, pancreas
and thyroid glands were compared in control and furazolidone-
treated cockerels (table 18) . Only the adrenal glands of
the treated birds showed a tendency to increase in weight
(g) , and this increase did not reach significance (P > 0.1) .
However, when the organ weights were expressed as per-
centrages of body weight, significant increases were found
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in the values for the adrenal (P < 0.05) and the thyroid
gland (P < 0.1) in the treated birds. The weights of the
heart and the pancreas (expressed as a percentage of body
weight) were not significantly affected by the drug
(P >0.1 in each instance).
Discussion
The amount of catecholamines in the adrenal glands
was not affected by furazolidone. Thus, any effect of
the drug on adrenal weight would most probably be due to
an effect on the cortex.
As the furazolidone-treated chickens grew less than the
controls, one would expect the organ weights of the treated
birds to be smaller than those of the controls. However,
the adrenal glands in chickens given furazolidone tended to
be larger than those in controls. This effect on the adrenal
weight was selective as the weights of the pancreas, heart
and thyroid glands (g) were not increased by the treatment.
The influence of the drug on the weights of the adrenal and
thyroid glands attained significance when the weights were
expressed as percentages of body weight, both glands being
enlarged in the treated birds.
Furazolidone produced no significant change in the
concentrations of ascorbic acid and cholesterol in the
adrenal glands or in the concentrations of cholesterol and
glucose in the plasma. Thus, the present findings neither
confirm nor refute the suggestion of Sidorov & Luders (1971)
that furazolidone is a "stressor" agent in the chicken.
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Experiments to determine the more sensitive indicators of
"stress" (viz, plasma corticosterone and differential leucocyte
count) are still required.
The furazolidone treatment produced a significant
increase in the weight of the thyroid glands when expressed
as a percentage of body weight. The implication of this
observation is not clear, although some of the known effects
of the thyroid hormones seem to concur with effects produced
by furazolidone in the chicken (e.g. the decrease in growth
and the increase in oxygen consumption of heart tissue).
Chapter VI
Some Untoward Effects of Furazolidone in Chickens
Furazolidone at doses above that used in therapy
produced some untoward effects in poultry. For example,
the drug has been reported to produce an anaemia in the
chicken when fed at a concentration of 0.04% w/w for 21 days
(Ehlhardt et al, 1975). In the turkey, furazolidone
(0.05% w/w) in the feed for 28 days increased aspartate
transaminase activity in plasma (Staley et al, 1978), and at
a concentration of 0.05 - 0.07% w/w for 42 days, it decreased
the arterial blood pressure (Simpson et al, 1979).
The present experiments examine whether or not the
therapeutic dose of furazolidone (0.04% w/w, 10 days)
produces these effects in chickens.
Results
Effect of furazolidone on arterial blood pressure in conscious
chickens
The arterial blood pressure was measured in conscious
chickens which had been given a control or a'furazolidone-
medicated diet. The blood pressure of birds given
furazolidone was not significantly different (P > 0.1) from
that of the controls (table 19).
93.
Effect of furazolidone on packed cell volume (PCV) and
haemoglobin (Hb) content of blood
The PCV and Hb content in the blood of chickens treated
with furazolidone were not significantly different from that
in controls (P > 0.1) (table 19).
Effect of furazolidone on the activity of aspartate
transaminase in plasma
As shown in table 13, the furazolidone did not affect
the activity of the enzyme in chicken plasma (P > 0.1).
Discussion
Treatment with furazolidone at the therapeutic dose
produced a small reduction in the arterial blood pressure of
the chicken, which was not statistically significant. The
drug treatment also had no effect on the PCV or the Hb
content of the blood, indicating that, at the therapeutic
dose, the drug did not produce anaemia in the chicken.
Furazolidone did not affect the activity of aspartate
transaminase in the plasma. This is a cytoplasmic enzyme,
and the present observation suggests that furazolidone did not
produce a detectable damage in cell membranes.
Thus, it is clear that, in the chicken, the therapeutic
dose of furazolidone does not produce the untoward effects
which have been reported in galliformes following admini¬
stration of the drug at greater doses.
General Discussion
Furazolidone has found many applications as an
antimicrobial agent in both man and animals. Nonetheless,
the pharmacological effects of the drug on the host have
received insufficient attention, and little work has been
done to find out the 'biochemical lesions' which precede
the manifestation of the toxic signs produced by the drug.
One established pharmacological effect of furazolidone
in rat and man is the inhibition of MAO activity in vivo
(Stern et al, 1967; Palm et al, 1967; Pettinger et al,
1968). Although furazolidone is not itself a MAO inhibit¬
or, it is believed to be converted to an active metabolite,
possibly 2-hydroxyethyl hydrazine, in the rat (Stern et al,
1967). However, Pettinger et al (1968) failed to detect
any metabolite which possessed MAO inhibiting properties
in the urine from patients treated with furazolidone.
The exact site where transformation of furazolidone to the
active metabolite takes place is not certain. The present
experiments (Chapter 1) have indicated that the alimentary
flora is the site of transformation. This was based on
the finding that the intramuscular administration of furazo¬
lidone to the chicken was ineffective in inhibiting MAO
activity, whereas oral furazolidone inhibited the enzyme.
To verify the hypothesis that furazolidone was transformed
by the alimentary flora, two sets of experiments were
performed. Firstly, MAO activity was measured along the
alimentary tract in the furazolidone-treated chickens.
It is known that the flora in the alimentary tract is
most abundant in the caecum and the crop (Jayne-Williams
& Fuller, 1971), and, if the hypothesis was valid,
greater inhibition of MAO would be expected in the parts
richest in the flora. This was indeed the case. Second¬
ly, an attempt was made to suppress the alimentary flora
by oral administration of neomycin. This antibiotic was
chosen because of its broad spectrum activity and poor
absorption from the gut. These experiments showed that
oral neomycin did antagonize the MAO inhibitory action of
furazolidone. It appears that less than 10% of oral
neomycin is absorbed from the alimentary tract, at least
in dogs and rats (Waksman, 1953; Freyburger & Johnson,
1956) . When the antibiotic was given intramuscularly at
one-tenth of the oral dose, it did not antagonize the
inhibitory action of furazolidone indicating that absorbed
neomycin could not have influenced the action of furazol¬
idone on MAO activity. In ducklings, oral neomycin also
antagonized the MAO inhibitory action of furazolidone,
suggesting that the alimentary flora of ducklings trans¬
formed furazolidone to an inhibitor of MAO as in the
chicken.
Although the role of the alimentary flora in trans¬
forming furazolidone has been indicated in more than one
experiment, the ultimate proof for its involvement in
transforming furazolidone to an MAO inhibitor would be
the use of germ-free birds, but these were not available.
In the absence of germ-free birds, the results obtained
with neomycin are worth confirming with another anti¬
biotic, e.g. oxytetracycline. Our contention that
furazolidone becomes an MAO inhibitor only after trans¬
formation by the alimentary flora has recently been
confirmed in the rat (Cohen, 1980), using the antibiotic
oxytetracycline to suppress the gut flora. It has been
realized in recent years that a number of compounds
containing nitro-group undergo metabolic transformation
(mainly reductive) by the action of the alimentary flora
(see e.g. Goldman, 1978; Facchini & Griffith, 1980).
It was of interest to note that furazolidone (0.04%
w/w, 10 days) inhibited MAO activity in the liver of
ducklings and not chickens, indicating that hepatic
clearance of the inhibitor was less efficient in the
former species than in the latter.
No mortality was found among ducklings given
furazolidone in the feed at a concentration of 0.04% w/w
for 10 days, or by crop tube at a dose of 200 mg/kg.
These observations are at variance with reports of a
high susceptibility to furazolidone in ducks (Dougherty,
1956; Kriz, Branda & Svestka, 1968). The toxicity of
the drug in ducks seems variable, and it is not difficult
to account for this now it is understood that the drug is
transformed to an active metabolite by the alimentary
flora. Free range conditions may encourage the prolifer¬
ation of these components of the flora which transform the
drug to an active metabolite, and under these free range
conditions, the ducklings may be more susceptible to the
drug than in the present experiments.
A significant rise was found in the amount of 5-HT
in the brain of chickens and ducklings following furazol¬
idone treatment (0.04% w/w, 10 days) (Chapter 2). The
amounts of noradrenaline and adrenaline were unaffected
by the drug. The increase in 5-HT is most probably an
outcome of MAO inhibition. The rise in brain monoamines
was possibly involved in the nervous signs observed in
ducks and pigs following furazolidone treatment (Lucas,
1956; Borland, 1979).
Furazolidone CO.04% w/w, 10 days) potentiated (to a
similar extent) the vasopressor action of tyramine whether
given intravenously or intraduodenally. The inhibition
of MAO in the alimentary tract would be expected to
interfere with the detoxification of pharmacologically
active amines present in the diet or formed from the
dietary amino acids in the intestine by bacterial
decarboxylases. However, although more of the tyramine
may have been absorbed into the portal circulation from
the duodenum when MAO in the alimentary tract was
inhibited, it seems that the amount reaching the systemic
circulation was not affected significantly, probably
because the MAO activity in the liver was not inhibited
by this treatment in the chicken. Another possible
experiment, which might be carried out to demonstrate the
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consequences of MAO inhibition in the chicken, would be
to test the effects of tyramine and noradrenaline of the
rate and amplitude of isolated auricles from furazolidone-
treated birds (Lock, 1963).
The addition of furazolidone to the diet (0.04% w/w,
10 days), was shown to produce a significant reduction in
feed intake and growth of the treated birds (Chapter 3).
The influence of the drug on growth has been reported by
several authors before, but little or no attention has
been paid to the effect of the drug on feed intake. In
the present experiments an attempt was made to correlate
the growth reduction with feed intake. The pair-feeding
experiment showed that the growth of chickens fed ad
libitum with control diet was matched very closely by
that in pair-fed birds, indicating the validity of the
technique of pair-feeding. Growth in chickens fed ad
libitum with furazolidone (0.04% w/w) was not significant¬
ly different from that in birds pair-fed with unmedicated
feed. Thus, the reduction in growth in the furazolidone-
treated birds could be accounted for by the reduction in
feed intake. However, a tendency of the furazolidone-
treated birds to grow less than pair-fed birds must not be
overlooked, as it may be of biological significance.
An explanation for the anorectic action of furazolid¬
one was sought in the increase in the 5-HT content of the
brain. The feed intake and growth of chickens medicated
concomitantly with furazolidone and methergoline (a potent
antagonist of central actions of 5-HT) were not different
from those in chickens given furazolidone only. Thus
the involvement of the rise in 5-HT in the anorectic
action of furazolidone seemed unlikely.
The commonly used indices of thiamin status were
employed in the present experiments to investigate the
possibility that furazolidone had influenced the thiamin
status of the birds (Chapter 4). The measurement of
the activities of enzymes in which TPP is a cofactor is
the best parameter for determining the thiamin status.
These enzymes include transketolase, pyruvate dehydro¬
genase and a-ketoglutarate dehydrogenase. The effect
of thiamin deficiency on the activity of transketolase
is particularly pronounced, and in the present experi¬
ments the activity of this enzyme and its stimulation by
TPP in vitro (TPP effect) has been measured in the blood.
An increase in the concentrations of pyruvate and lactate
in the blood is also considered an indicator of thiamin
deficiency because the decarboxylation of pyruvate to
acetyl coA may be limited when TPP is deficient.
Furazolidone treatment raised the blood concentrations
of pyruvate and lactate, and increased the TPP effect on
transketolase activity. It did not, however, affect
significantly the basal transketolase activity in the
erythrocytes. The drug also produced a reduction in
the feed intake and growth of the treated birds. Taken
together, these findings seem to indicate that the
treatment had produced a degree of thiamin deficiency in
the birds. It is possible, however, that these bio¬
chemical effects could have arisen indirectly from
inanition rather than from the drug per se. Measuring
the indices of thiamin status in pair-fed chickens would
help to discriminate between these possibilities.
The attempt to reverse the furazolidone-induced
signs of thiamin deficiency by injecting the birds with
thiamin HCl was unsuccessful. It is unlikely that the
dosage of the vitamin was insufficient, as a lower dose
of thiamin was effective in reversing the signs of
thiamin deficiency produced by amprolium (Polin et al,
1962). Furazolidone could have interfered with the
utilization of the vitamin by the birds, and to test
this possibility, the phosphorylated form of thiamin (TPP)
will be given to the drug-treated chickens in further
experiments. However, these experiments may be incon¬
clusive as one cannot administer TPP intracellularly.
Other enzymes whose activity might be studied to verify
the effect of furazolidone on the thiamin status of the
birds are pyruvate dehydrogenase (which catalyzes the
transformation of pyruvate to acetyl coA in the mitoch¬
ondria) and possibly thiamin phosphokinase (which catalyzes
the phosphorylation of the thiamin in the cytoplasm).
The proposition of Sidorov & Lhders (1971) that
furazolidone is a 'stressor' agent in the chicken was
tested by measuring several indicators of 'stress'.
However, the results obtained were inconclusive (Chapter 5)
There was an increase in the weight of the adrenal glands
(about 20%), and a trend towards depletion of cholesterol
from the gland which did not reach significance. The
indicators of 'stress' used in these experiments (which
are commonly used in mammals) have been shown to be
applicable to the fowl (Freeman, 1970; Siegel, 1970).
Other changes, mostly resulting from the increase in
adrenal activity, can also be used as indicators of 'stress'
These include an elevation of plasma corticosterone,
involution of lymphoid tissue (the thymus, the spleen and
particularly the bursa of fabricus), and changes in the
number of leucocytes. More experiments are required to
elucidate the position of furazolidone as a 'stressor'
agent in the chicken.
Furazolidone given to the chicken at the therapeutic
dose did not produce the untoward effects which have been
reported in poultry given the drug at larger doses (Chapter
6). Thus it seems that the toxicity is dosage and time-
dependent. This was reassuring, indicating that the drug
was safer than might have been supposed from the previously
published work.
From a practical point of view, the reduction in feed
intake and growth is probably the most serious effect of
furazolidone in the birds. It seems unlikely, however,
that this effect would be as great as the inhibition in


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1. Chemical structure of furazolidone
((N-5-nitro-2-furfurylidene)3-anino~2-oxazolidine)
Figure 2. A calibration curve for the determination
of 4-hydroxyquinoline produced by tissue homogenates
from the oxidative deamination of kvnuramine.
Ordinate : relative fluorescence intensity;
abscissa : concentrations of 4-hydroxyquinoline (yq/
incubation medium).
12.3
Figure 3. A calibration curve for the determination of
formaldehyde produced by chicken liver supernatant fraction
incubated with aminopyr'ine. Ordinate : absorbence (A)
measured at a wavelength of 415 nm; abscissa : concen¬
trations of formaldehyde lug/5 ml) reacted with 'Nash
Reagent'.
IZ-f-
Figure 4. The influence of ZnSO^ on the rate of oxidation
of adrenaline (1 yg/ml). Ordinate : fluorescence
intensity arising fron the oxidation of the amine with
potassium ferricvanide for 3 min at pH 3.5; abscissa :
final concentration of ZnSO^ in the oxidation mixture
(nig/ml) . The plotted points are mean values obtained
from 4 observations, the s.e.m. being depicted by the
vertical bars. The rate of oxidation of adrenaline
increased with the increase in concentration of ZnPO.
up to 0.17 mg/ml, thereafter it plateauej.
125
intensity
Figure 5. The fluorescence/of adrenaline and nor¬
adrenaline reacted in the trihydroxyindole reaction in
the presence of ZnSO^ (0.17 mg/ml) at pH 3.5. Ordinate :
fluorescence intensity; abscissa : time of
oxidation with potassium ferricyanide (min). The plotted
points are mean values (n = 6) for adrenaline (1 yg/ml)
(A) and noradrenaline (1 yg/ml) (N). The vertical bars
depict the s.e.m. Maximum fluorescence of adrenaline
occurred in 3 min, whereas the fluorescence of nor¬
adrenaline increased slowly with time.
Figure 6. Fluorescence intensity of different concentrations
of adrenaline (A) and noradrenaline (N) solutions, oxidized
with potassium ferricyanide for 3 min at pH 6.5.
Ordinate : fluorescence insensitivitv; abscissa :
concentrations of the amine (yg base/ml). The plotted
points are mean values of 6 observations, the standard
errors of the mean being depicted by vertical bars. The
regression line of fluorescence upon amine concentrations
was calculated by the method of least square.
IVJ
450 600 450 600
wavelength (nm)
Figure 7. The fluorescence spectra of noradrenaline (N),
adrenaline (A) and dopamine (D) reacted by the tri-
hydroxyindole (THI) method. Ordinate :
fluorescence intensity; abscissa : emission wavelenath
(450 - 600 nm). From above down in (1), the fluorescence
spectra from noradrenaline 1.00, 0.50 and 0.25 yg/ml and
dopamine 100 yg/ml, reacted by THI method at dH 6.5.
From above down in (2), the fluorescence spectra from
adrenaline 1.00, 0.50 and 0.25 yg/ml and dopamine 100 yg/ml
reacted by the THI method at pH 3.5. Dopamine produced
fluorescence spectra similar to that of the reagent blank.
|2S
Figure 8. The fluorescence of noradrenaline in extracts
of chicken brain and from authentic solutions of the amine
reacted by the 'trihydroxyindole1 method. Ordinate :
fluorescence insensitivity; abscissa : emission
wavelength (450 - 600 nm). The spectra labelled 1 and 2
in (A) were obtained from brain extracts oxidized at pH 6.5
and 3.5 respectively. Spectra (3), (4) and (5) are those
of noradrenaline (0.05 yg/ml), noradrenaline (0.1 yg/ml)
and reagent blank, respectively. The fluorescence spectra
in (B) were obtained from noradrenaline solutions, passed
through the CG50 columns. The peaks of the spectra of
noradrenaline shifted from 435-493 nm as the amounts of
the amine increases from 0.05 - 0.2 yc/ml.
Figure 9. a calibration curve for the determination
of cholesterol concentration in plasma. Ordinate :
absorbftnce (A) measured at a wavelength of 560
abscissa : amount of cholesterol (mg) in the mixture.
°'°0 100 "200 300 .. ,400 „ 5Mglucose concentration (jjg/ml)
Figure lo. A calibration curve for the determination
of glucose concentration in chicken plasma^
Ordinate : absorbance (A) measured at 510 nm;






























Figure 11. Monoamine oxidase (MAO) activity in homogenates
of chicken organs after discontinuing furazolidone in the feed
(0.04% w/w, 10 days). Ordinate : MAO activity as a percentage
of the control value. The columns represent mean values for
duodenal mucosa (D), liver (L), heart (H) and brain (B) at 0,
7 and 14 days after discontinuing furazolidone medication.
The vertical bar at the head of each column depicts the
standard error of the mean (3 birds). The asterisks mark



























































Figure 12. The activity of monoamine oxidase (MAO) in the
mucosa of different parts of the chicken alimentary tract.
Each column and vertical bar represents a mean value and























































Figure 13. Effect of furazolidone (0.04% w/w in the ^eed
for 10 days) on the activity of monoamine oxidase (I1AO) in
chicken tissues. Ordinate : MAO activity expressed as %
control. Each column and vertical bar depicts a mean and
the number of birds used. The residual enzyme activity
in the caeca was less than that in other tissues
(P < 0.02 - < 0.001), and that in the liver was not
different from the control (P > 0.1).
134-
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Figure 14. The activity of monoamine oxidase (MAO) in homo-
genates of chicken organs 24 h after givina the birds a single
oral (open columns) or intramuscular (cross-hatched columns)
dose of furazolidone (200 mg/Kg). Ordinate : MAO activity
expressed as % control. Each column represents a mean
value obtained from 6 birds, the s.e.m. bein~ denicted by
vertical bars. Intramuscular furazolidone did not affect
the activity of MAO significantly in any of the organs
studied (P > 0.1).
135
1-25 126 125 1-25 126 125 1-25 12-5 125 1-25 12-5 125 mg/kg
duodenum liver heart brain
Figure 15. Inhibition of monoamine oxidase (MAO) activity
in chicks (closed circles) and ducklings (open circles)
24 h after the administration of furazolidone by crop tube.
Ordinate : MAO activity expressed as % control.
Abscissa : doses of furazolidone (mg/Kg, on a geometric
scale) administered to birds aged 2-12 days. The circles
represent mean values obtained from 5 chicks or 3 ducklings,
the s.e.m. being depicted by vertical bars. The asterisks
mark a species difference in the inhibition of MAO activity
in the duodenum, which was significant at the 1% (*) and
0.1% (**) levels.
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Figure 16. Inhibition of monoamine oxidase (MAO) activity
in chicks (closed circles) and turkey poults (closed circles)
24 h after the administration of furazolidone by crop tube.
Ordinate : MAO activity expressed as % control.
Abscissa : doses of furazolidone (mq/Kg, on a qeometric scale)
administered to birds aged 2-12 days. The circles represent
the mean values obtained from 5 chicks or turkey poults, the
s.e.m. being depicted by vertical bars. The asterisks mark
a species difference in the inhibition of MAO activity in the
heart which was significant at the 5% (*) and 1% (**) level.
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Figure 17. The vasopressor actions of noradrenaline and
tyramine injected intravenously in preparation made from
control (closed circles) and furazolidone-treated (ooen
circles) chickens anaesthetized with sodium phenobarbitone
(180 mg/Kg). Ordinate : increase in arterial blood
pressure (mm Hg). Abscissa : doses of noradrenaline acid
tartarate and tyramine hydrochloride (yg/Kg, on a aeometric
scale). Each circle and vertical bar represents a mean
value and the s.e.m., respectively, from 4 - 6 pullets.
Treatment with furazolidone (0.04% w/w, 10 days) potentiated
the action of tyramine (P < 0.01) at all but the lowest
dose, the response to noradrenaline was unaffected (P > 0.01) .
min
Fig, 18. Arterial blood pressure of anaesthetized
preparations of cockerels given a control (upper tracing)
or furazolidone-medicated diet (lov/er tracing) .
Ordinates: arterial blood pressure (mm Hg). Abscissa:
time (min). The arrows mark the administration of tyramine
hydrochloride (25 mg/kg) by intraduodenal injection.
Treatment with furazolidone (0.04% w/w, 10 days) potentiated
the vasopressor action of tyramine.
(31
Figure 19. ^he vaso depressor actions of"5-HT, histamine
and tryptamine given intravenously in anaesthetized
preparations of control (closed circles) and furazolidone-
treated (open circles) chickens. Ordinate : decrease in
arterial blood pressure(nun Hg). Abscissa : doses of 5-HT
creatinine sulphate, histamine dihydrochloride and tryotamine
hydrochloride (yg/Kg, on a geometric scale). The circles
and bars represent the mean values and the s.e.m.,
respectively, from 4-5 birds. Treatment with furazolidone
(0.04% w/w, 10 days) did not affect the action of the















































Figure 20. The effect of furazolidone (0.04% w/w in the
feed for 10 days) on food consumption and growth in 6
groups of chickens weeks old at the start of the
experiment) and 4 groups of ducklings (4 days at commence¬
ment) . Ordinate : feed intake (Kg)/Kg body weight/10 days
growth (g)/Kg body weight/10 days, and growth (g)(Kg feed/
10 days). Each column represents a mean value, the s.e.m.
being depicted by a vertical bar. The control birds (open
columns) consumed more food and grew more than the
furazolidone-treated birds (cross-hatched columns).
IW
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Figure 21. The influence of furazolidone (0.04% w/w,
10 days) on the cumulative feed intake and growth in
chickens housed individually (7% weeks old at the beginning
of the experiment, n = 5 or 6). Upper ordinate : feed
intake (Kg/Kg initial body weight), lower ordinate :
growth (g/Kg initial body weight); abscissa : days of the
experiment. In the treated birds (open circles) growth
was significantly less than in the controls (closed circles)





Figure 22. Growth in chickens on restricted diets of
unmedicated food. The chickens were pair-fed with birds
on (A) unmedicated food, and (B) given furazolidone
(0.04%w/w) . Ordinate : growth (g/Kn- initial body weight);
abscissa : days of the experiment. The crosses and
vertical bars represent the mean and s.e.m., respectively,
for 6 birds. The T-line chickens were weeks old on
day 1 of the experiment. On days 5 to 10 of the
experiment, the chickens grew less on diet (B) than on
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Fig. 23. Growth in chickens fed ad libitum (circles) and
pair-fed (crosses) with a restricted diet equivalent to that
consumed ad libitum. Ordinate = growth (g/kg initial body
weight). Abscissa: days of the experiment. In (A), both
groups were on an unmedicated diet. In (B), the chickens fed
ad libitum received furazolidone (0.04% w/w) in the diet, and
the pair-fed birds on unmedicated feed. The T-line chickens
were 7\ weeks old on day 1 of the experiment and they were 6
in each group. There was no significant difference in growth
between the ad libitum and the pair-fed birds (P > 0.1).
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Figure 24. The influence of furazolidone (0.04% w/w, 10
days) on the concentrations of lactate (open columns) and
pyruvate (cross-hatched columns) in the blood of chickens,
turkey poults and ducklings. Ordinate : the concentrations
of lactate or pyruvate expressed as % control. Each
column represents a mean value obtained from 5-6 birds,
the s.e.m. being depicted by vertical bars. In each
species the concentrations of lactate and pyruvate were
significantly increased following furazolidone treatment


















Figure 25. Effect of furazolidone (0.04% w/w, 10 days) on
the activity of transketolase (TK) and the thiamin pyro¬
phosphate (TPP) effect in chicken haemolysate. Left
ordinate : TK activity (u/1) . Right ordinate : TPP effect
expressed as % increase in TK activity upon addition of TPP.
The columns represent the mean values obtained from 5 control
(open) and furazolidone-treated chickens (cross-hatched).
The vertical bar at the head of each column depicts the
s.e.m. The asterisk marks a significant increase in the































































Figure 26. Effect of furazolidone (0.04% w/w, 10 days)
on the oxygen consumption of chicken oraans.
Ordinate : oxygen consumption of homogenized tissue
expressed as a percentage of the control values. The
amounts of tissue (mg duodenal mucosa, liver, heart or
brain) in the incubates is shov/n on the abscissa. Each
column represents a mean value obtained from 5 or 6 chickens,
and the vertical bar at the head of the columns depicts the
standard error of the means. Furazolidone increased the
oxygen consumption of heart (200 or 400 mg, P < 0.02)
and reduced that of liver (400 mg, P < 0.001).
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INHIBITION OF MONOAMINE OXIDASE BY FURAZOLIDONE IN THE
CHICKEN AND THE INFLUENCE OF THE ALIMENTARY FLORA
THEREON
B.H. ALI & A.L. BARTLET
Department of Veterinary Pharmacology, University of Edinburgh, Edinburgh, EH9 1QH
1 The addition of furazolidone to the feed at the therapeutic level (0.04% w/w, 10 days) inhibited
monoamine oxidase (MAO) activity by 47 to 72% in chicken duodenal mucosa, heart and brain, but
in the liver the enzyme activity was unaffected by the treatment.
2 Furazolidone (200 mg/kg) administered by crop tube inhibited MAO activities in duodenal
mucosa, liver, heart and brain.
3 Furazolidone (200 mg/kg) injected intramuscularly did not inhibit MAO activity in the chicken.
4 Pretreatment of the chickens with intramuscular neomycin did not antagonize the inhibition of
MAO activity produced by furazolidone (200 mg/kg, crop tube).
5 Pretreatment with neomycin by crop tube to suppress the alimentary flora significantly reduced
the effect of furazolidone on MAO activity, suggesting that the drug was transformed by the alimen¬
tary flora to an active metabolite which subsequently inhibited MAO activity in other organs.
6 Furazolidone in the feed (0.04% w/w, 10 days) or administered by crop tube (200 mg/kg) had no
effect on the activity of aminopyrine demethylase in chicken liver.
7 The activity of aspartate transaminase in plasma was unaffected by the addition of furazolidone to
the feed (0.04% w/w, 10 days).
Introduction
Furazolidone [(iV-5-nitro-2-furfurylidene)3-amino-2-
oxazolidine] is widely used in the prevention and
treatment of certain bacterial and protozoal diseases
which affect poultry (Harwood & Stunz, 1954;
Rogers, Belloff, Paul, Yurchenco & Gever, 1956). At
slightly above the therapeutic level the drug inhibits
growth, produces anaemia and arrests spermato¬
genesis in the chicken (Cooper & Skulski, 1956; Mac-
Donald & Beilharz, 1961; Ehlhardt, Beuving & Haye,
1975) and may also produce cardiac dilatation and
ascites (Feron & Van Stratum, 1966). The biochemical
lesion associated with these toxic signs has not been
defined.
In rat and man, furazolidone inhibits monoamine
oxidase (MAO, monoamine :02 oxidoreductase
(deaminating) EC 1.4.3.4.). However, the drug does
not inhibit MAO in vitro suggesting that a transform¬
ation product, possibly 2-diethylhydrazine, is respon¬
sible for the enzyme inhibition in vivo (Stern, Holli-
field, Wilk & Buzard, 1967; Pettinger, Soyangco &
Oates, 1968).
In the present experiments we have investigated the
effect of furazolidone on the activity of MAO in the
chicken. A preliminary account of some of the work




Thornber chickens (8 weeks old, either sex) were
obtained from the Poultry Research Centre, Kings
Buildings, Edinburgh. The birds were fed a layer
mash (Douglas of Dalkeith, Edinburgh) which was
free from growth promoting and anticoccidial drugs.
In some experiments furazolidone was administered
in the feed at the therapeutic level of 0.04% w/w for 10
days, the controls receiving unmedicated feed. In
other experiments the drug (200 mg/kg) was adminis¬
tered by intramuscular injection or crop tube, control
birds receiving 0.9% w/v aqueous NaCl or aqueous
acacia (20% w/v), respectively.
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Preparation of tissues
Chickens were killed by decapitation and the tissues
rapidly removed and chilled on ice. The lumen of the
duodenum was washed with chilled saline before cut¬
ting it open and scraping away the mucosa with a
glass slide. The heart was opened and blotted to
remove blood. The tissues were cut into small pieces
and homogenized with six strokes in a Teflon hom-
ogenizer in an ice bath. Homogenates (20% w/v) of
each organ in 0.5 m phosphate buffer (pH 7.4) were
prepared for the estimation of MAO activity. For the
estimation of aminopyrine demethylase activity, a
liver homogenate (25% w/v) in isotonic KC1 (1.15%
w/v) was centrifuged at 10,000 g for 20 min in an
MSE High Speed 18 Refrigerated centrifuge at 5°C,
and the microsome-rich supernatant used.
Measurement of enzyme activity
Monoamine oxidase activity MAO activity was esti¬
mated according to the method of Krajl (1965), in
which the production of 4-hydroxyquinoline from the
oxidative deamination of kynuramine is measured.
The incubation mixture contained kynuramine dihyd-
robromide (100 pg), 0.5 m phosphate buffer pH 7.4
(0.5 ml), homogenate (equivalent to 0.78 mg duodenal
mucosa, 3.13 mg liver or brain or 12.5 mg heart) and
de-ionised water to a final volume of 3 ml. An incu¬
bate without substrate served as the blank. The reac¬
tion mixtures were incubated at 37°C for 30 min
under air and with shaking. The incubates were then
deproteinised with perchloric acid (0.6 m) as recom¬
mended by Century & Rupp (1968) followed by centri-
fugation at 900 g for 10 min at 5°C. Supernatant (1
ml) was mixed with 1 n NaOH (2 ml) and placed in a
quartz cuvette. The solution was activated at 315 nm
and the peak in the fluorescence scan at 380 nm
measured in an Aminco-Bowman spectrofluorimeter.
The presence of substances affecting the fluorescence
of 4-hydroxyquinoline was sought by mixing equal
volumes of tissue blank and 4-hydroxyquinoline solu¬
tion. In all cases the fluorescence of the mixture was
half that of the undiluted solution of 4-hydroxyquino¬
line, demonstrating an absence of augmentation or
quenching of fluorescence.
Aminopyrine demethylase activity was estimated in
the 10,000 g supernatant fraction of liver. The con¬
ditions of the incubation were those described by
Mazel (1971), except that the concentrations of amin¬
opyrine and semicarbazide in the incubation mixture
were both 10 mM. The formaldehyde produced in the
reaction was estimated by the method of Nash (1953).
Aspartate transaminase [AST (EC 2.6.1.1.)] activity
was estimated in chicken plasma by the method de¬
scribed by Wilkinson, Baron, Moss & Walker (1972).
This measures the rate at which absorbance at 340
nm decreases as NADH is oxidized to NAD. Blood
was withdrawn from a wing vein by means of a hepar-
inised syringe fitted with a 21G needle (external diam¬
eter 0.8 mm) and spun down in a refrigerated centri¬
fuge (5°C) at 900 g for 20 min to separate plasma.
Statistical analysis
The values in the text, tables and figures are
means + the standard error of the mean (± s.e. mean)
with the number of observations in parentheses. Sig¬
nificant difference between means was estimated by
the t test and probability (P) values are given. A value
of P < 0.05 is regarded as significant.
Drugs and chemicals
A premix containing 4% w/w furazolidone (Neftin)
was used for the addition of the drug to the feed, and
a micronized preparation of furazolidone (particle size
5 pm) for administration by injection and crop tube.
Acetylacetone (Koch Light), aminopyrine
(4-dimethylamine-antipyrine 97%) (Ralph Emanuel),
L-aspartic acid (Sigma), D-glucose-6-phosphate mono-
sodium salt (Sigma), 4-hydroxyquinoline (Sigma),
kynuramine dihydrobromide (Sigma), malate de¬
hydrogenase (Sigma), neomycin sulphate (70% soluble
powder, veterinary) (Squibb & Sons), nicotinamide
(Sigma), nicotinamide adenine dinucleotide phosphate
(Sigma), nicotinamide adenine dinucleotide, reduced
form (Sigma) and 2-oxoglutaric acid (Sigma) were
used. The other chemicals were Analytical Reagent
grade.
Results
In the chicken the activity of MAO in heart and liver
is reported to increase with age (Ignarro & Shideman,
1968), and our data (Table 1) confirmed this trend.
Table 1 Monoamine oxidase (MAO) activity in homo¬
genates of organs from chickens of different ages
MAO activity
(4-Hydroxyquinoline, pmol g~ 1 tissue h~





36.9 ± 5.1 (6)
2.5 ± 0.4 (6)
1.2 ± 0.1 (6)
12.7 ± 1.1 (7)
90.7 ± 12.5 (8) <0.02
22.3 ± 1.9 (7) <0.001
3.3 ± 0.3 (7) <0.001
15.6 ±2.0 (7) >0.2
The values in the table are means ± s.e. means (No. of
animals).
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Thus in our other experiments all the birds were
killed at the same age, 8 weeks, at which age the
activities of MAO in control organs was consistent.
Effect offurazolidone in the feed on monoamine oxidase
activity
When furazolidone was added to the feed at a thera¬
peutic concentration of 0.04% w/w for 10 days, the
activity of MAO was reduced significantly in duo¬
denal mucosa, heart and brain, and not in liver
(Table 2). Another experiment investigated the recov¬
ery in enzyme activity after discontinuing the medi¬
cated feed. This experiment confirmed the effect of
feeding furazolidone on MAO activity, which was in¬
hibited in the duodenal mucosa (P < 0.001), heart
(P < 0.02) and brain (P < 0.02), and not in liver
(P > 0.1) (Figure 1). Seven days after discontinuing
furazolidone in the feed a significant recovery of
MAO activity was only evident in the duodenal
mucosa (P < 0.02). Fourteen days after discontinuing
the drug the recovery of MAO activity was complete
in each organ, there being no significant difference
from the control values (P > 0.1 for each organ).
Effect of furazolidone by crop tube or intramuscular
injection on MAO activity
The drug was administered at a dose of 200 mg/kg
body weight, which is about half the reported LD50 in
the chicken (Radchuk, 1965). Furazolidone adminis¬
tered by crop tube inhibited MAO activity in the liver
as well as that in duodenal mucosa, heart and brain
(Table 3). The time course of the inhibition was differ¬
ent in various organs, however, being maximal in the
liver 12 h after drug administration and in the duo¬
denal mucosa and brain after 24 h.
In another experiment furazolidone (200 mg/kg)
was administered by crop tube or intramuscular injec¬
tion and MAO activities estimated 24 h later. This
experiment confirmed that the drug given by crop
tube inhibited MAO activity in the liver as well as in
the other organs studied (P < 0.001 for each organ, 6
birds). In contrast, furazolidone injected intramuscu¬
larly did not affect MAO activity in any of the organs
studied (P > 0.1 for each organ, 6 birds).
Effect of neomycin on the inhibition of monoamine
oxidase by furazolidone
In this experiment the birds were given neomycin,
either 20 mg by intramuscular injection or 200 mg by
crop tube twice daily for 5 days before MAO estima¬
tion. Furazolidone (200 mg/kg) was administered by
crop tube to saline- and neomycin-treated birds 24 h
before the enzyme estimation. Neomycin did not
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Figure 1 Monoamine oxidase activity (MAO) in
homogenates of chicken organs after discontinuing fur¬
azolidone in the feed (0.04% w/w, 10 days). Ordinate
scale: MAO activity as a percentage of the control
value. The columns represent mean values for duodenal
mucosa (D), liver (L), heart (H) and brain (B) at 0, 7 and
14 days after discontinuing furazolidone medication.
The vertical bar at the head of each column depicts s.e.
mean (3 birds). The asterisks mark significant inhibition
of MAO, at the 2% (*), 0.2% (**) and 0.1% (***) levels.
chickens pretreated with saline or neomycin and
given acacia mucilage (crop tube) were pooled and
used as controls. As shown in Table 4, furazolidone
administered by crop tube inhibited MAO activity in
each organ as before (P < 0.01), and pretreatment
Table 2 Effect of feeding furazolidone (0.04% w/w, 10
days) on monoamine oxidase (MAO) activity in homo¬
genates of chicken tissue
MAO activity
(4-Hydroxyquinoline, pmol <?"' tissue h~')
Control Furazolidone P
Duodenum 92.6 ± 10.0 (10)
Liver 21.9 ± 3.9 (8)
Heart 3.4 ± 0.3 (7)
Brain 15.5 ±2.0 (7)
58.9 ± 7.5 (9) <0.02
22.3 ±1.9 (8) >0.9
1.7 ± 0.3 (6) <0.002
9.4 ± 0.7 (6) <0.02
The values in the table are means ± s.e. means (No. of
animals).
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with neomycin by the intramuscular route did not
affect the MAO inhibition (P > 0.1). On the other
hand, pretreatment with neomycin by crop tube sig¬
nificantly reduced the MAO inhibiting action of fura¬
zolidone in each organ (P < 0.01 to < 0.001). Follow¬
ing oral administration of neomycin and furazolidone
the activity of MAO was less than the control value in
the liver (P < 0.002) and brain (P < 0.05) but not in
the duodenal mucosa (P > 0.1) and heart (P > 0.05).
Thus the suppression of the MAO inhibiting action of
furazolidone by the oral neomycin was complete in
the duodenal mucosa and heart and not in the liver
and brain.
Effect of furazolidone on aspartate transaminase and
aminopyrine demethylase activities
Addition of furazolidone (0.04% w/w, 10 days) to the
feed had no significant effect on the activity of aspar¬
tate transaminase in plasma (Table 5).
Table 3 Effect of time on monoamine oxidase (MAO) inhibition produced by furazolidone (200 mg/kg) given by
crop tube
MAO activity
(4-Hydroxyquinoline, pmol g_1 tissue h~l)
Time (h) after
furazolidone Duodenal mucosa Liver Heart Brain
0 95.95 + 6.21 (3) 29.72 ± 4.70 (3) 2.51 ± 0.21 (3) 15.41 + 1.76(3)
12 40.43 + 0.92 (3) 9.93 + 0.31 (3) 0.90 + 0.01 (3) 8.80 + 0.41(3)
24 34.66 ± 1.67 (3) 11.65 ± 0.53 (3) 0.92 ±0.10 (3) 7.02 ± 0.85 (3)
48 36.63 ± 2.65 (3) 15.27 ± 1.12 (3) 0.82 ± 0.06 (3) 8.04 ±0.18 (3)
The values in the table are means ± s.e. means (No. of animals).
Table 4 Monoamine oxidase (MAO) activity in homogenates of chicken organs 24 h after administration of
furazolidone (200 mg/kg, crop tube) and the influence of neomycin thereon
MAO activity P P
(4-Hydroxyquinoline, pmol g~l tissue h~') Intramuscular Oral
(3) Furazolidone + (4) Furazolidone + neomycin neomycin
_ . . (I) Control (2) Furazolidone *neomycin (i.m.) **neomycin (oral) [c/.(3) and (2)] [c/. (4) and (2)]Duodenal
mucosa 93.71 + 5.29 (15) 32.83 + 6.65 (6) 38.10 + 2.20 (3) 75.19 +11.54 (6) >0.1 <0.01
Liver 24.88 + 1.90 (15) 8.95 + 1.26 (6)' 9.69 + 0.25 (3) 15.15 + 1.38 (6) >0.1 <0.01
Heart 2.66 + 0.13 (15) 0.81 + 0.09 (6) 1.18 + 0.30(3) 2.32 + 0.14 (6) >0.1 <0.001
Brain 11.77 + 0.71 (15) 7.11 + 0.65 (6) 7.38 + 0.37 (3) 10.05 + 0.27 (6) >0.1 <0.002
The values in the table are means ± s.e. means (No. of animals).
* Neomycin, 20 mg/bird by intramuscular injection, twice daily for 5 days before the MAO estimation.
** Neomycin, 200 mg/bird by crop tube, twice daily for 5 days before the MAO estimation.
Table 5 Effect of furazolidone on the activities of aminopyrine demethylase in liver and aspartate transaminase in
plasma from chickens
Aminopyrine demethylase Aspartate transaminase
Expt Treatment (H. CHO pmol* ml~1 h~') ('"/')
f Control feed 0.37 ± 0.04 (6) 56.2 ± 5.2 (5)
\ Furazolidone, 0.04% w/w in feed, 10 days 0.37 ± 0.05 (6) 59.1 ± 5.2 (8)
7 / Acacia mucilage (crop tube) 0.30 ± 0.03 (5)
\ Furazolidone, 200 mg/kg (crop tube) 0.35 ± 0.08 (6>
* Per ml of 10,000 g supernatant of liver homogenate (25% w/v).
The values in the table are means ± s.e. means (No. of animals).
The drug had no significant effect on the activities of either enzyme.
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In two experiments the effect of furazolidone on
aminopyrine demethylase activity in a microsome-
rich supernatant fraction of chicken liver was investi¬
gated (Table 5). In one experiment the drug was ad¬
ministered in the feed at the therapeutic dose, and in
the other by crop tube at a dose of 200 mg/kg 24 h
before estimation of the enzyme activity. In both ex¬
periments the activity of aminopyrine demethylase
was unaffected by the drug.
Discussion
Furazolidone administered in th'e feed at the thera¬
peutic dose inhibited MAO activity in the duodenal
mucosa, heart and brain, but in the liver the enzyme
activity was unaffected by the treatment. MAO is in¬
hibited by a transformation product of furazolidone
(Stern et al., 1967; Pettinger et al., 1968), and MAO
inhibition would be expected at the site of transform¬
ation. As MAO activity was not inhibited in the liver,
it seems improbable that the transformation of fura¬
zolidone occurred here. Following withdrawal of
medication, the enzyme activity recovered more
promptly in the duodenal mucosa than in the other
organs. The recovery of activity was probably due to
synthesis of new enzyme, as dialysis does not restore
activity to MAO inhibited by furazolidone (Stern et
al., 1967).
Furazolidone administered by crop tube inhibited
the activity of MAO in the duodenal mucosa, liver,
heart and brain. Thus furazolidone given as a bolus
inhibited the hepatic enzyme although it did not do
so when fed continuously. In the hepatocytes, the fur¬
azolidone metabolite may inhibit mitochondrial
MAO, or, it may be metabolized further and/or
excreted with bile. The present observations suggest
that clearance of the metabolite was insufficient to
protect hepatic MAO from inhibition when the drug
was given as a bolus (200 mg/kg), but was sufficient
when it was given as a feed additive (0.04% w/w, 10
days). Following furazolidone by crop tube a maxi¬
mum inhibition of MAO in the liver was found after
12 h and in other organs after 24 h. This observation
suggests that hepatic clearance of the furazolidone
metabolite resulted in a briefer inhibition of MAO in
the liver than elsewhere.
Furazolidone administered by intramuscular injec¬
tion did not affect the activity of MAO in any of the
organs studied. This observation suggests that the
conversion of the drug to an MAO inhibitor did not
occur in chicken tissues. However, this finding may
not extend to other species as furazolidone given by
intravenous or intraperitoneal injection is reported to
inhibit MAO in the rat (Stern et al., 1967).
The alimentary flora might have produced the
metabolite which inhibited MAO activity. To test this
hypothesis furazolidone was given by crop tube after
suppressing the alimentary flora with neomycin. Pre-
treatment with neomycin by crop tube antagonized
the action of furazolidone on MAO activity, but neo¬
mycin injected intramuscularly at l/10th of the oral
dose did not do so. Less than 10% of neomycin is
absorbed from the alimentary tract (Waksman, 1953;
Freyburger & Johnson, 1956), so in the present ex¬
periments absorbed neomycin could not have
influenced the action of furazolidone on MAO ac¬
tivity. The inhibition ofMAO activity by furazolidone
was suppressed by unabsorbed neomycin, which sup¬
ports the hypothesis that the alimentary flora trans¬
forms furazolidone to an active metabolite which is
subsequently responsible for the inhibition of MAO
activities in other organs.
Inclusion of furazolidone in the feed (0.04% w/w, 10
days) did not affect the activity of aspartate trans¬
aminase in plasma. This is a cytoplasmic enzyme, and
the present observation suggests that furazolidone did
not produce a detectable damage in cell membranes.
However, furazolidone at a higher dose (0.05% w/w,
28 days) has been reported to increase significantly
the activity of this enzyme in turkey plasma (Staley,
Noren, Bandt & Sharp, 1978).
Many drugs inhibit both MAO and mixed function
oxidase (Kato, Takanaka & Shoji, 1969). Aminopyr¬
ine demethylase activity in chicken liver, however,
was unaffected by furazolidone treatment (0.04% w/w,
10 days, or 200 mg/kg by crop tube). Thus furazo¬
lidone at the recommended therapeutic dose would
not be expected to potentiate the actions of other
drugs metabolized by mixed function oxidase.
B.H.A. is supported by the British Council. We wish to
thank Mr Ian Warwick for technical assistance and the
Wellcome Animal Unit for housing the birds. Furazolidone
and neomycin were kindly supplied by Eaton Laboratories
and Squibb Ltd., respectively.
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Inhibition of monoamine oxidase by
furazolidone in the chicken: influence of the
alimentary flora
B H. A LI & A.L. BARTLET
Department of Veterinary Pharmacology, Royal (Dick)
School of Veterinary Studies. Edinburgh. EHV IQH.
^
Furazolidone is widely used in the prevention and
treatment of certain bacterial and protozoal diseases
*hich afTcct poultry. Oral administration of the drug
in rat and man has been shown to inhibit monoamine
oxidase (MAO) [monoamine: Oj oxidorcductase
(deaminating) EC 1.4.3.4.]. Furazolidone docs not in¬
hibit MAO in vitro, however, suggesting that a trans¬
formation product is responsible for the enzyme inhi¬
bition in vivo (Stern, Hollificld, Wilk & Buzard, 1967;
Pcitingcr, Soyangco & Oatcs, 1968k
[British Pharmacopoeia (Veterinary). 1977] inhibited
MAO activity by 50% in heart, 39% in brain. 36%
in duodenal mucosa and not in liver. The inhibition
of the enzyme in heart, brain and duodenal mucosa
were all significant at the 2% level.
Furazolidone (200 mg/kg) injected intramuscularly
did not aflccl MAO activity, but administered by crop
tube it inhibited the enzyme by 47-72% (Table I).
These observations suggest that the transformation
of furazolidone to a MAO inhibitor occurred in the
gut. Prctrcatmcnt with neomycin to suppress the ali¬
mentary flora reduced the effect of furazolidone on
MAO activity (Table 1). Thus in the chicken MAO
inhibition by furazolidone seems to depend on the
presence of the alimentary flora.
B.H.A. is a British Council student. We thank Eaton
Laboratories and Squibb Ltd. for gifts of furazolidone and
neomycin respectively and the Wellcome Unit for housing
the birds.
Table 1 Monoamine oxiduse activity in homogenates of chicken organs 24 h after administration of furazolidone,
and the influence of neomycin thereon
Expt. Drugs
Monoamine oxiduse activity l/iniol i-hydroxyguinoline/g/h)
Duodenal mucosa Ucer Heart
1 Saline, i.m.
Furazolidone (200 mgAsk i.m.
2 Acacia mucilage, orally V '
Furazolidone (200 mgAgk
orally
3 Neomycin (200 mg/bird.
twice daily fot 5 days),
orally
Neomycin (as above) +
furazolidone (200 mgAgk
orally with the last
dose of neomycin
71.00 ± 3.29(6)
73.02 ± 4.61 (6)
104.60 ± 8.77(6)








0.81 ± 0.09 (6)**
Brain
7.97 ± 0.41 (6)
7.72 ± 0.52 (6)
13.42 ± 0.41 (6)
' 7.11 ± 0.65(6)"
85.33 ± 8.17(6) 22J2 ± 2.91 (6) 2.71 ±0.19(6) 10.50 ±0.59(6)
75.19 ± 11.54(6) 15.15 ± 1.38(6)" 2.32 X 0.14(6)» 10.05 ± <X27(6)
The values in the table are means ± s.e. means (No. of observations).
•P<0.01. "P< 0.001.
We have investigated the effect of furazolidone on
MAO activity in the chicken. The birds (Thornbcrs,
8 weeks old) were killed at the end of a feed trial
or 24 h after administration of the drug by intramus¬
cular injection or crop tube. Selected organs were
homogenized for the estimation of MAO activity by
the method of Kramal (1965), in which formation of
4-hydroxy-quinolinc from kynuraminc is measured
spcctrofluoromctrically.
The addition of furazolidone to the feed at the
A. therapeutic concentration of 0.04% w/w for 10 days
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Some actions of furazolidone in poultry
B H ALI & A L BARTLE7
Department of t elerinary Pharmucoloyy, Unitersit \ of Edin¬
burgh. EHVIQH
Furazolidone has recently been shown to inhibit
monoamine oxidase (MAO) activity in the chicken
(Ali & Bartlet, 1980), and. in the present experiments,
in turkey poults and ducklings. When administered
by crop tube furazolidone was about equipotent in
inhibiting MAO activity in these three species
(Figure 1).
Inclusion of furazolidone in the feed at a concen¬
tration of 0.04% w/w for 10 days produced anorexia
in chickens, turkey poults and ducklings, but no mor¬
tality. The treatment produced a similar degree of
MAO inhibition in the hearts, brains and duodenal
mucosae from the three species, enzymatic activity
being inhibited by 29 to 59% (P < 0.05 to <0.001).
Only in the duckling was a significant inhibition of
MAO activity found in the liver (P < 0.01) Furzoli-
done 0.04% w/w for 10 days is the therapeutic treat¬
ment for galliformes (Veterinary Data Sheet. 1980).
the recommended dose for ducks being 0.01% w w of
the drug for 7 days.
Monoamines extracted from brain with perchloric
acid were purified on a cation exchange resin (Amber-
lile CG-50. ammonium form). 5-Hydroxvtryptamine
(5-HT) was estimated by its fluorescence in 3 M HO
and catecholamines by the trihydroxyindole method
The concentration of 5-HT in brains of ducklings fed
furazolidone (0.04% w w for 10 days) was 0.57 + 0.06
pg'g tissue (mean ± s.e.. 5 birds), and in paired con¬
trols 0.39 + 0.04 pg g. This increase in brain 5-HT
(P < 0.05) was selective, as concentrations of adrena¬
line and noradrenaline in the bram were unchanged
after feeding furazolidone to the ducklings (P > 0.1).
The pressor actions of graded doses of tyramine
and noradrenaline were measured in chickens anaes¬
thetized with phenobarbitone sodium (180 rng'Tg.
i.v.). Responses to tyramine in preparations made
from chickens fed furazolidone (0.04% w w for 10
rhf^+
1 25 12 5 125
Ch<*
U
125 12 5 125
Turkey poutt
125 12 5 125 mg/kg
Duckling
Figure 1 The inhibition of monoamine oxidase (MAO) activity in chicks, turkey poults and ducklings 24 h after
furazolidone administered by crop tube. Ordinate: MAO activity estimated by the method of Krajl (1965).
expressed as a percentage of the value in control birds Abscissa: doses of furazolidone (mg/kg) administered to
birds aged 2 to 12 days. The columns represent mean values for duodenal mucosa (D), liver (L), heart (H) or brain
(B) from 5 chicks, 5 turkey poults and 3 ducklings; the vertical bars at the head of the columns represent the s.e
Furazolidone inhibited MAO activity in the tissues of the three species to about the same extent, except that in the
heart it was greater in turkey poults than in chicks (P < 0.05) and in duodenal mucosa more marked in ducklings
than in chicks or turkey poults (P < 0.05).
days) were about 70% greater than those in control
preparations The pressor action of noradrenaline was
unaffected by the treatment.
B.H A is a British Council student We thank Eaton
Laboratories for furazolidone. Mr M M MacCowan for a
supply of poultry food and the Wellcome Animal Research
Unit for housing the birds
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